Eagle Bulk Shipping (EGLE) – Eagle Bulk Shipping reports strong 2022-2Q results

Monday, August 08, 2022

Eagle Bulk Shipping (EGLE)
Eagle Bulk Shipping reports strong 2022-2Q results

Eagle Bulk Shipping Inc. (“Eagle”) is a US-based drybulk owner-operator focused on the Supramax/Ultramax mid-size asset class, which ranges from 50,000 and 65,000 deadweight tons in size; these vessels are equipped with onboard cranes allowing for the self-loading and unloading of cargoes, a feature which distinguishes them from the larger classes of drybulk vessels and provides for greatly enhanced flexibility and versatility- both with respect to cargo diversity and port accessibility. The Company transports a broad range of major and minor bulk cargoes around the world, including coal, grain, ore, pet coke, cement, and fertilizer. Eagle operates out of three offices, Stamford (headquarters), Singapore, and Hamburg, and performs all aspects of vessel management in-house including: commercial, operational, technical, and strategic.

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Results were up sharply versus last year and slightly above our forecast. Net revenues were $198.7m in the most recent quarter, up 53% versus last year and in line with our $205.0m estimate. Improved sales reflect higher TCE shipping rates ($30,207 vs. $21,580) and more operating days (5,707 vs. 4,778) due to more owned and chartered-in vessels (60 vs. 55). Favorable sales led to a jump in adjusted EBITDA (which excludes hedges) to $102.6m from $6.6m surpassing our $93.4m estimate. The EBITDA surprise was due to lower-than-expected voyage expenses. Adjusted net income was $81.6m ($4.98/diluted share) versus our $73m. 

Charter rates have slipped but still remain above historical averages. Shipping rates declined in the second quarter as fighting in Ukraine and overall global economic concerns affected prices. Eagle has locked in 72% of its shipping rates for the third quarter as compared to an 83% rate in the second quarter leaving it a bit more exposed to spot prices. The fourth quarter is typically the highest-priced quarter due to North American grain shipments. Management believes the market for dry bulk shipping is also favorable with China opening up, Russian and Ukraine grain shipments resuming, and Brazil iron ore supply growing. Management points out that new vessel construction is limited and new orders wouldn’t be completed until 2024….

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Gray Television (GTN) – Political Better Than Expected

Monday, August 08, 2022

Gray Television (GTN)
Political Better Than Expected

Gray Television is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets in the United States. Our television stations serve 113 television markets that collectively reach approximately 36 percent of US television households. This portfolio includes 80 markets with the top-rated television station and 100 markets with the first and/or second highest rated television station. We also own video program companies Raycom Sports, Tupelo Honey, PowerNation Studios and Third Rail Studios.

Michael Kupinski, Director of Research, Noble Capital Markets, Inc.

Patrick McCann, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 exceeds expectations. The company reported quarterly revenue of $868 million, 11% above our estimate of $782 million. Adj. EBITDA was also strong, at $309 million, which beat our estimate of $280 million by 10.4%.

Inundated with Political. The skeptical management became a believer that Political could meet or exceed 2020 levels. Management raised 2022 Political advertising forecast from $575 million to $652 million. …

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kratos Defense & Security (KTOS) – When Will the Promise be Realized?

Monday, August 08, 2022

Kratos Defense & Security (KTOS)
When Will the Promise be Realized?

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms, and systems for United States National Security related customers, allies, and commercial enterprises. Kratos is changing the way breakthrough technologies for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research, and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training and combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.kratosdefense.com.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2Q22 Results. Revenue of $224.2 million, up 9.3% y-o-y, and came in above the $205-$215 million guidance. Revenue from acquisitions offset supply chain issues, staffing challenges, and a decline in the Training business. Adjusted EBITDA came in at $17.7 million, above guidance, versus $17.6 million a year ago. GAAP EPS loss was $0.04 and adjusted EPS net income was $0.07, compared to net income of $0.01 and $0.06, respectively, a year ago.

Awards Coming In. Kratos received a number of new awards, including three large space and satellite programs, new turbine engine work, and additional awards in the microwave business. The Company remains in pursuit of new awards across its multiple business lines.  …

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Ocugen (OCGN) – 2Q22 Reported With New Pipeline Program Moving Forward

Monday, August 08, 2022

Ocugen (OCGN)
2Q22 Reported With New Pipeline Program Moving Forward

Ocugen, Inc. is a biotechnology company focused on developing and commercializing novel gene therapies, biologicals, and vaccines. The lead product, Covaxin, is a killed-virus vaccine for COVID-19 in-licensed from Bharat Biotech (India). The lead product in its gene therapy program, OCU400, is in Phase 1/2 clinical trials for retinitis pigmentosa.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second Quarter Reflects Increases In Pipeline Activity.  Ocugen reported a loss of $19.5 million or $(0.09) per share, greater than our estimated loss of $16.7 million or $(0.07) per share.  The difference was due to higher expenses from clinical trials and increased headcount as the company added development staff.  The company ended the quarter with $115.0 million in cash.

Covaxin Clinical Studies Move Forward.  Ocugen is currently conducting a Phase 2/3 immuno-bridging study for US approval.  Discussions continue with Health Canada regarding additional information that may be required for Canadian approval.  In Mexico, Covaxin has received emergency use authorization for adults, with submission for pediatric use under review.  Due to the shortages of other COVID-19 vaccines in Mexico, this territory is a near-term opportunity for Covaxin….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Permex Petroleum (OILCF) – Coverage initiated with an Outperform rating

Monday, August 08, 2022

Permex Petroleum (OILCF)
Coverage initiated with an Outperform rating

Michael Heim, CFA, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Company is at a growth inflection point. The company is about to begin a drilling program that could significantly grow its assets and cash flow generation. We anticipate the company to reach a position of being cash flow positive in 2023.  Permex has the capital already in place to begin its expansion. As of March 31, 2022, the company had C$8.4 million in cash and virtually no debt. We believe Permex has adequate capital at its disposal to begin the first stage of its drilling program.

Assets that were acquired in the down cycle are now worth significantly more.  Permex management seeks to acquire assets during energy downcycles (such as the period we witnessed in the late teens) and exploit them during the upcycles (such as we are currently witnessing). According to management, Permex acquired over 11,000 acres at an average price of approximately $2,000/acre in areas that have been sold recently for prices 20-30 times higher.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Gevo Reports Second Quarter 2022 Financial Results



Gevo Reports Second Quarter 2022 Financial Results

Research, News, and Market Data on Gevo

GEVO
TO HOST CONFERENCE CALL TODAY AT 4:30 P.M. EDT/2:30 P.M. MDT

ENGLEWOOD, Colo., Aug. 08, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the second quarter of 2022 and recent corporate highlights.

Recent Corporate Highlights

  • On July 18, 2022, Gevo signed a financeable fuel sales agreement with American Airlines, Inc. to supply 100 million gallons per year of SAF for five years from Gevo’s future commercial operations. The table below summarizes the supply agreements executed since April 1, 2022:

Recently Announced Sales
Agreements

Date Signed

Customer

Product

Volume (MGPY)

Term (Years)

June 2022

Japan Airlines

SAF

5.3

5

June 2022

Finnair

SAF

7.0

5

July 2022

Aer Lingus

SAF

6.3

5

July 2022

American Airlines

SAF

100.0

5

July 2022

Alaska Airlines

SAF

37.0

5

  • Gevo now has more than 350 million gallons per year (“MGPY”) of financeable SAF and hydrocarbon fuel supply agreements, which based on current market projections and operating assumptions, represent approximately $2.1 billion in expected revenue per year, inclusive of the value of environmental benefits. These types of contracts are expected to assist Gevo in obtaining project debt financing.
  • On June 5th, 2022, Gevo executed a registered direct offering of 33.3 million shares to certain institutional investors. That offering closed on June 8th, 2022, providing net proceeds of $139.0 million. As part of the offering, Gevo issued 33.3 million Series 2022-A Warrants with an exercise price of $4.37 per share.
  • The Company’s Net-Zero 1 project is on schedule and the Company continues to work towards completion of the various milestones for 2022, including, among others, executing certain commercial development, build, own and operate agreements, and selecting an EPC contractor for the project.
  • On July 25, 2022, the Company completed the purchase of approximately 245 acres near Lake Preston, South Dakota for its Net-Zero 1 production facility.
  • Gevo’s renewable natural gas (“RNG”) project in Northwest Iowa is now generating biogas from all three dairies and the RNG produced is expected to ramp toward nameplate capacity of 355,000 MMBtu throughout the second half of 2022.

2022 Second Quarter Financial
Highlights

  • Ended the quarter with cash, cash equivalents, restricted cash and marketable securities of $546.8 million compared to $475.8 million as of the end of Q4 2021
  • Revenue of $0.1 million for the quarter compared to $0.3 million in Q2 2021
  • Loss from operations of $(16.1) million for the quarter compared to $(19.1) million in Q2 2021
  • Non-GAAP cash EBITDA loss1 of $(11.0) million for the quarter compared to $(17.2) million in Q2 2021
  • GAAP net loss per share and non-GAAP adjusted net loss per share2 of $(0.06) for the quarter compared to $(0.09) in Q2 2021

Management Comment

Commenting on the second quarter of 2022 and recent corporate events, Dr. Patrick R. Gruber, Gevo’s Chief Executive Officer, said, “Given our continued success in securing SAF supply agreements as well as the additional interest that we are witnessing in the marketplace, there should not be any question about the potential size of the market for renewable fuels. The opportunities in front of us over the next decade and beyond are large and rapidly growing. Our goal is to build SAF production capacity at a rate that will establish Gevo and its partners as a market leader and powerhouse in the renewable fuels sector. It all starts with NZ1, the engineering and design is going well. Based on what we see today we expect to stay on schedule for the 2025 start-up.” Dr. Gruber also remarked that, “Gevo’s RNG project continues to ramp to nameplate capacity of 355,000 MMBtu. All three dairies are now producing biogas which is then upgraded and injected into the sales pipeline. That RNG is sold into the California market by our marketing partner, BP. We continue to collect the performance data for our application to the California Air Resource Board to receive LCFS credits and the Renewable Fuel Standard Program for RINs.”

Second Quarter 2022 Financial
Results

During the three months ended June 30, 2022, we sold 9 thousand gallons of SAF, isooctane, and isooctene from our Luverne Facility. Revenue decreased $0.3 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, due to the Luverne Facility being operated for the Company’s development projects on a as needed basis.

Cost of goods increased $1.0 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to an increase in direct labor and utility expenses as the Luverne Facility was not fully staffed during the second quarter of 2021 due to the COVID-19 pandemic. The majority of our costs are related to the production of SAF, isooctane, and isooctene as we continue to develop and tailor our Luverne Facility demonstration operations to support our focus on advancing technology, testing and optimizing alternative feedstocks, yeast strains, and unit operations as well as partnership development for integrated GHG reductions. Cost of goods sold also includes a $2.1 million net realizable gain adjustment made to our finished goods and work in process inventory. There were no inventory net realizable value adjustments recorded during the three months ended June 30, 2021, as the Luverne Facility was temporarily shut down due to the COVID-19 pandemic.

Research and development expense increased $0.6 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to an increase of laboratory expenses and additional stock-based compensation expense.

Selling, general and administrative expense increased $4.4 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to increases in personnel costs related to strategic new hiring, stock-based compensation, and professional fees.

Preliminary stage project costs are related to our Verity and future Net-Zero Projects and consist primarily of employee expenses and consulting costs. Preliminary stage project costs decreased $5.2 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily because we began capitalizing our RNG and NZ1 project costs in 2021.

Other operations expense increased $0.6 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily related to unallocated engineering and consulting services.

Depreciation and amortization expense increased $0.3 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to the amortization of our patents.

We incurred no gain (loss) from the change in the fair value of the derivative warrant liability in the three months ended June 30, 2022. The last of the liability warrants expired in February 2022.

There were no significant changes in interest expense during the three months ended June 30, 2022, compared to the three months ended June 30, 2021.

Interest and dividend income increased $0.1 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to the interest earned on our investments partially offset by the amortization of the bond premiums.

Other income (expense) increased $2.7 million during the three months ended June 30, 2022, compared to the three months ended June 30, 2021, primarily due to our receipt of $2.9 million from the US Department of Agriculture’s Biofuel Producer Program to support biofuel producers who faced unexpected losses due to the COVID-19 pandemic. The Biofuel Producer Program grants are not tax-exempt.

Non-GAAP cash EBITDA loss3 in the three months ended June 30, 2022, was $(11.0) million, compared with a $(17.2) million non-GAAP cash EBITDA loss in the same period in 2021.

During the six months ended June 30, 2022, net cash used for operating activities was $17.1 million compared to $19.5 million for the six months ended June 30, 2021. The $2.4 million decrease was primarily due to increased costs associated with our production of isobutanol and hydrocarbon products for market development, process technology and related process engineering work. In addition, we had increases in personnel expenses to support the growth in business activity, partnership development and Verity development expenses.

Webcast and Conference Call
Information

Hosting today’s conference call at 4:30 p.m. EDT (2:30 p.m. MDT) will be Dr. Patrick R. Gruber, Chief Executive Officer, L. Lynn Smull, Chief Financial Officer, Tim Cesarek, Chief Commercial Officer, and John Richardson, Director of Investor Relations. They will review Gevo’s financial results and provide an update on recent corporate highlights.

To participate in the live call, please register through the following event weblink: https://register.vevent.com/register/BI82c9f363e71c46baa4a8d5e9764fcdbd. After registering, participants will be provided with a dial-in number and pin.

To listen to the conference call (audio only), please register through the following event weblink: https://edge.media-server.com/mmc/p/65vvqgmx.

A webcast replay will be available two hours after the conference call ends on August 8, 2022. The archived webcast will be available in the Investor Relations section of Gevo’s website at www.gevo.com.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel, and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full lifecycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that it possesses the technology and know-how to convert various carbohydrate feedstocks through a fermentation process into alcohols and then transform the alcohols into renewable fuels and materials, through a combination of its own technology, know-how, engineering, and licensing of technology and engineering from Axens North America, Inc., which yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that Argonne National Laboratory GREET model is the best available standard of scientific based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to a variety of matters, including, without limitation, whether our fuel sales agreements are financeable, the timing of our Net-Zero 1 project, our financial condition, our results of operation and liquidity, our business development activities, our Net-Zero Projects, our RNG Project, our fuel sales agreements, our plans to develop our business, our ability to successfully develop, construct and finance our operations and growth projects, our ability to achieve cash flow from our planned projects, the ability of our products to contribute to lower greenhouse gas emissions, particulate and sulfur pollution, and other statements that are not purely statements of historical fact These forward-looking statements are made based on the current beliefs, expectations and assumptions of the management of Gevo and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Gevo undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Gevo believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gevo in general, see the risk disclosures in the Annual Report on Form 10-K of Gevo for the year ended December 31, 2021 and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Gevo.

Non-GAAP Financial Information

This press release contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), including non-GAAP cash EBITDA loss, non-GAAP adjusted net loss and non-GAAP adjusted net loss per share. Non-GAAP cash EBITDA loss excludes depreciation and amortization and non-cash stock-based compensation from GAAP loss from operations. Non-GAAP adjusted net loss and adjusted net loss per share exclude non-cash gains and/or losses recognized in the quarter due to the changes in the fair value of certain of Gevo’s financial instruments, such as warrants, convertible debt and embedded derivatives, from GAAP net loss. Management believes these measures are useful to supplement its GAAP financial statements with this non-GAAP information because management uses such information internally for its operating, budgeting and financial planning purposes. These non-GAAP financial measures also facilitate management’s internal comparisons to Gevo’s historical performance as well as comparisons to the operating results of other companies. In addition, Gevo believes these non-GAAP financial measures are useful to investors because they allow for greater transparency into the indicators used by management as a basis for its financial and operational decision making. Non-GAAP information is not prepared under a comprehensive set of accounting rules and therefore, should only be read in conjunction with financial information reported under U.S. GAAP when understanding Gevo’s operating performance. A reconciliation between GAAP and non-GAAP financial information is provided in the financial statement tables below.

1Cash EBITDA
loss is a non-GAAP measure calculated by adding back depreciation and
amortization and non-cash stock-based compensation to GAAP loss from
operations. A reconciliation of cash EBITDA loss to GAAP loss from operations
is provided in the financial statement tables following this release.

2Adjusted net loss per share is a non-GAAP measure calculated by
adding back non-cash gains and/or losses recognized in the quarter due to the
changes in the fair value of certain of our financial instruments, such as warrants,
convertible debt and embedded derivatives, to GAAP net loss per share. A
reconciliation of adjusted net loss per share to GAAP net loss per share is
provided in the financial statement tables following this release.

3 Cash EBITDA loss is a non-GAAP measure calculated by adding
back depreciation and amortization and non-cash stock compensation to GAAP loss
from operations. A reconciliation of cash EBITDA loss to GAAP loss from
operations is provided in the financial statement tables following this release.


Gevo, Inc.

Condensed Consolidated Balance Sheets Information
(Unaudited, in thousands, except share and per share
amounts)

 

As of June 30, 2022

 

As of December 31, 2021

Assets

 

 

 

Current assets

 

 

 

Cash and cash equivalents

$

172,984

 

 

$

40,833

 

Marketable securities (current)

 

297,631

 

 

 

275,340

 

Restricted cash (current)

 

5,894

 

 

 

25,032

 

Accounts receivable, net

 

188

 

 

 

978

 

Inventories

 

2,649

 

 

 

2,751

 

Prepaid expenses and other current assets

 

5,275

 

 

 

3,607

 

Total current assets

 

484,621

 

 

 

348,541

 

Property, plant and equipment, net

 

176,054

 

 

 

139,141

 

Long-term marketable securities

 

 

 

 

64,396

 

Long-term restricted cash

 

70,256

 

 

 

70,168

 

Operating right-of-use assets

 

2,098

 

 

 

2,414

 

Finance right-of-use assets

 

27,477

 

 

 

27,297

 

Intangible assets, net

 

8,364

 

 

 

8,938

 

Deposits and other assets

 

5,741

 

 

 

5,581

 

Total assets

$

774,611

 

 

$

666,476

 

 

 

 

 

Liabilities

 

 

 

Current liabilities

 

 

 

Accounts payable and accrued liabilities

$

18,750

 

 

$

28,288

 

Operating lease liabilities (current)

 

423

 

 

 

772

 

Finance lease liabilities (current)

 

6,293

 

 

 

3,413

 

Loans payable – other (current)

 

158

 

 

 

158

 

Total current liabilities

 

25,624

 

 

 

32,631

 

2021 Bonds payable (long-term)

 

66,853

 

 

 

66,486

 

Loans payable – other (long-term)

 

238

 

 

 

318

 

Operating lease liabilities (long-term)

 

1,786

 

 

 

1,902

 

Finance lease liabilities (long-term)

 

16,342

 

 

 

17,797

 

Other long-term liabilities

 

 

 

 

87

 

Total liabilities

 

110,843

 

 

 

119,221

 

 

 

 

 

Stockholders’ Equity

 

 

 

Common stock, $0.01 par value per share; 500,000,000 and 250,000,000 shares authorized at June 30, 2022, and December 31, 2021, respectively; 235,165,951 and 201,988,662 shares issued and outstanding at June 30, 2022, and December 31, 2021, respectively.

 

2,353

 

 

 

2,020

 

Additional paid-in capital

 

1,249,880

 

 

 

1,103,224

 

Accumulated other comprehensive loss

 

(2,256

)

 

 

(614

)

Accumulated deficit

 

(586,209

)

 

 

(557,375

)

Total stockholders’ equity

 

663,768

 

 

 

547,255

 

Total liabilities and stockholders’ equity

$

774,611

 

 

$

666,476

 


Gevo, Inc.

Condensed Consolidated Statements of Operations Information
(Unaudited, in thousands, except share and per share
amounts)

 

Three Months Ended June 30, 2022

 

Six Months Ended June 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Revenue and cost of goods
sold

 

 

 

 

 

 

 

Ethanol sales and related products, net

$

71

 

 

$

 

 

$

240

 

 

$

 

Hydrocarbon revenue

 

18

 

 

 

346

 

 

 

81

 

 

 

359

 

Total revenues

 

89

 

 

 

346

 

 

 

321

 

 

 

359

 

Cost of production (including non-cash compensation expense)

 

2,640

 

 

 

1,617

 

 

 

5,730

 

 

 

2,518

 

Depreciation and amortization

 

1,088

 

 

 

1,177

 

 

 

2,179

 

 

 

2,270

 

Total cost of goods sold

 

3,728

 

 

 

2,794

 

 

 

7,909

 

 

 

4,788

 

Gross loss

 

(3,639

)

 

 

(2,448

)

 

 

(7,588

)

 

 

(4,429

)

Operating expenses

 

 

 

 

 

 

 

Research and development expense (including stock-based compensation)

 

1,966

 

 

 

1,332

 

 

 

3,158

 

 

 

2,710

 

Selling, general and administrative expense (including stock-based compensation)

 

9,209

 

 

 

4,846

 

 

 

18,576

 

 

 

8,660

 

Preliminary stage project costs

 

314

 

 

 

5,472

 

 

 

821

 

 

 

8,199

 

Other operations (including stock-based compensation)

 

601

 

 

 

 

 

 

1,190

 

 

 

 

Loss (gain) on disposal of assets

 

 

 

 

4,954

 

 

 

 

 

 

4,954

 

Depreciation and amortization

 

386

 

 

 

46

 

 

 

737

 

 

 

104

 

Total operating expenses

 

12,476

 

 

 

16,650

 

 

 

24,482

 

 

 

24,627

 

Loss from operations

 

(16,115

)

 

 

(19,098

)

 

 

(32,070

)

 

 

(29,056

)

Other income (expense)

 

 

 

 

 

 

 

(Loss) gain from change in fair value of derivative warrant liability

 

 

 

 

43

 

 

 

16

 

 

 

(10

)

Interest expense

 

(2

)

 

 

(6

)

 

 

(4

)

 

 

(11

)

Investment income (loss)

 

78

 

 

 

 

 

 

330

 

 

 

 

Gain on forgiveness of SBA loan

 

 

 

 

641

 

 

 

 

 

 

641

 

Other income (expense), net

 

2,878

 

 

 

167

 

 

 

2,894

 

 

 

126

 

Total other income (expense), net

 

2,954

 

 

 

845

 

 

 

3,236

 

 

 

746

 

Net loss

$

(13,161

)

 

$

(18,253

)

 

$

(28,834

)

 

$

(28,310

)

Net loss per share – basic and diluted

$

(0.06

)

 

$

(0.09

)

 

$

(0.14

)

 

$

(0.15

)

Weighted-average number of common shares outstanding – basic and diluted

 

209,809,994

 

 

 

198,137,420

 

 

 

205,889,651

 

 

 

190,892,223

 


Gevo, Inc.

Condensed Consolidated Statements of Comprehensive Income
(Unaudited, in thousands, except share and per share
amounts)

 

Three months Ended June 30,

 

Six Months Ended June 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

 

 

 

 

 

 

 

 

Net loss

$

(13,161

)

 

$

(18,253

)

 

$

(28,834

)

 

$

(28,310

)

Other comprehensive income (loss)

 

 

 

 

 

 

 

Unrealized gain (loss) on available-for-sale securities, net of tax

 

(669

)

 

 

(307

)

 

 

(1,643

)

 

 

(307

)

Adjustment for net gain (loss) realized on available-for-sale securities and included in net income, net of tax

 

 

 

 

 

 

 

1

 

 

 

 

Total change in other comprehensive income (loss)

 

(669

)

 

 

(307

)

 

 

(1,642

)

 

 

(307

)

Comprehensive loss

$

(13,830

)

 

$

(18,560

)

 

$

(30,476

)

 

$

(28,617

)


Gevo, Inc.

Condensed Consolidated Statements of Stockholders Equity
Information

(Unaudited, in thousands, except share amounts)

 

For the three months ended June 30, 2022 and
2021

 

Common Stock

 

Paid-In Capital

 

Accumulated Other Comprehensive Loss

 

Accumulated Deficit

 

Stockholders’ Equity

 

Shares

 

Amount

 

 

 

 

Balance, March 31, 2022

201,752,722

 

 

$

2,019

 

 

$

1,107,051

 

 

$

(1,587

)

 

$

(573,048

)

 

$

534,435

 

Issuance of common stock and common stock warrants, net of issuance costs

33,333,336

 

 

 

333

 

 

 

138,675

 

 

 

 

 

 

 

 

 

139,008

 

Non-cash stock-based compensation

 

 

 

 

 

 

4,220

 

 

 

 

 

 

 

 

 

4,220

 

Issuance of common stock under stock plans, net of taxes

79,893

 

 

 

1

 

 

 

(66

)

 

 

 

 

 

 

 

 

(65

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

(669

)

 

 

 

 

 

(669

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(13,161

)

 

 

(13,161

)

Balance, June 30, 2022

235,165,951

 

 

$

2,353

 

 

$

1,249,880

 

 

$

(2,256

)

 

$

(586,209

)

 

$

663,768

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, March 31, 2021

198,050,449

 

 

$

1,981

 

 

$

1,101,939

 

 

$

 

 

$

(508,229

)

 

$

595,691

 

Issuance of common stock and common stock warrants, net of issuance costs

 

 

 

 

 

 

(45

)

 

 

 

 

 

 

 

 

(45

)

Issuance of common stock upon exercise of warrants

3,700

 

 

 

 

 

 

4

 

 

 

 

 

 

 

 

 

4

 

Non-cash stock-based compensation

 

 

 

 

 

 

858

 

 

 

 

 

 

 

 

 

858

 

Issuance of common stock under stock plans, net of taxes

(89,673

)

 

 

(1

)

 

 

(1,824

)

 

 

 

 

 

 

 

 

(1,825

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

(307

)

 

 

 

 

 

(307

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(18,253

)

 

 

(18,253

)

Balance, June 30, 2021

197,964,476

 

 

$

1,980

 

 

$

1,100,932

 

 

$

(307

)

 

$

(526,482

)

 

$

576,123

 

 

 

For the six months ended June 30,2022 and
2021

 

Common Stock

 

Paid-In Capital

 

Accumulated Other Comprehensive Loss

 

Accumulated Deficit

 

Stockholders’ Equity

 

Shares

 

Amount

 

 

 

 

Balance, December 31, 2021

201,988,662

 

 

$

2,020

 

 

$

1,103,224

 

 

$

(614

)

 

$

(557,375

)

 

$

547,255

 

Issuance of common stock and common stock warrants, net of issuance costs

33,333,336

 

 

 

333

 

 

 

138,675

 

 

 

 

 

 

 

 

 

139,008

 

Issuance of common stock upon exercise of warrants

4,677

 

 

 

 

 

 

3

 

 

 

 

 

 

 

 

 

3

 

Non-cash stock-based compensation

 

 

 

 

 

 

8,264

 

 

 

 

 

 

 

 

 

8,264

 

Issuance of common stock under stock plans, net of taxes

(160,724

)

 

 

 

 

 

(286

)

 

 

 

 

 

 

 

 

(286

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

(1,642

)

 

 

 

 

 

(1,642

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(28,834

)

 

 

(28,834

)

Balance, June 30, 2022

235,165,951

 

 

$

2,353

 

 

$

1,249,880

 

 

$

(2,256

)

 

$

(586,209

)

 

$

663,768

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2020

128,138,311

 

 

$

1,282

 

 

$

643,269

 

 

$

 

 

$

(498,172

)

 

$

146,379

 

Issuance of common stock, net of issuance costs

68,170,579

 

 

 

682

 

 

 

456,963

 

 

 

 

 

 

 

 

 

457,645

 

Issuance of common stock upon exercise of warrants

1,866,758

 

 

 

18

 

 

 

1,103

 

 

 

 

 

 

 

 

 

1,121

 

Non-cash stock-based compensation

 

 

 

 

 

 

1,420

 

 

 

 

 

 

 

 

 

1,420

 

Issuance of common stock under stock plans, net of taxes

(211,172

)

 

 

(2

)

 

 

(1,823

)

 

 

 

 

 

 

 

 

(1,825

)

Other comprehensive loss

 

 

 

 

 

 

 

 

 

(307

)

 

 

 

 

 

(307

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

(28,310

)

 

 

(28,310

)

Balance, June 30, 2021

197,964,476

 

 

$

1,980

 

 

$

1,100,932

 

 

$

(307

)

 

$

(526,482

)

 

$

576,123

 


Gevo, Inc.

Condensed Consolidated Cash Flow Information
(Unaudited, in thousands)

 

Six Months Ended June 30,

 

 

2022

 

 

 

2021

 

Operating Activities

 

 

 

Net loss

$

(28,834

)

 

$

(28,310

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Loss on disposal of assets

 

 

 

 

4,954

 

(Gain) on forgiveness of SBA Loans

 

 

 

 

(641

)

Stock-based compensation

 

7,945

 

 

 

1,617

 

Depreciation and amortization

 

2,916

 

 

 

2,372

 

Noncash interest expense

 

2,637

 

 

 

 

Other noncash (income) expense

 

352

 

 

 

(41

)

Changes in operating assets and liabilities:

 

 

 

Accounts receivable

 

790

 

 

 

(320

)

Inventories

 

102

 

 

 

275

 

Prepaid expenses and other current assets, deposits and other assets

 

(1,828

)

 

 

(3,142

)

Accounts payable, accrued expenses and long-term liabilities

 

(1,194

)

 

 

3,768

 

Net cash used in operating
activities

 

(17,114

)

 

 

(19,468

)

Investing Activities

 

 

 

Acquisitions of property, plant and equipment

 

(46,165

)

 

 

(14,167

)

Acquisition of patent portfolio

 

(10

)

 

 

 

Proceeds from sale and maturity of marketable securities

 

169,082

 

 

 

 

Purchase of marketable securities

 

(131,257

)

 

 

(422,362

)

Net cash used in investing
activities

 

(8,350

)

 

 

(436,529

)

Financing Activities

 

 

 

Proceeds from issuance of 2021 Bonds

 

 

 

 

68,995

 

Debt and equity offering costs

 

(10,993

)

 

 

(34,757

)

Proceeds from issuance of common stock and common stock warrants

 

150,000

 

 

 

487,549

 

Proceeds from exercise of warrants

 

3

 

 

 

1,119

 

Net settlement of common stock under stock plans

 

(286

)

 

 

 

Payment of loans payable – other

 

(72

)

 

 

(53

)

Payment of finance lease liabilities

 

(87

)

 

 

 

Net cash provided by
financing activities

 

138,565

 

 

 

522,853

 

Net increase (decrease) in cash and cash equivalents

 

113,101

 

 

 

66,856

 

Cash, cash equivalents and restricted cash at beginning of period

 

136,033

 

 

 

78,338

 

Cash, cash equivalents and restricted cash at end of period

$

249,134

 

 

$

145,194

 


Gevo, Inc.

Reconciliation of GAAP to Non-GAAP Financial Information
(Unaudited, in thousands, except share and per share
amounts)

 

Three Months Ended June 30, 2022

 

Six Months Ended June 30,

 

 

2022

 

 

 

2021

 

 

 

2022

 

 

 

2021

 

Non-GAAP
Cash EBITDA:

 

 

 

 

 

 

 

Loss from operations

$

(16,115

)

 

$

(19,098

)

 

$

(32,070

)

 

$

(29,056

)

Depreciation and amortization

 

1,474

 

 

 

1,223

 

 

 

2,916

 

 

 

2,374

 

Stock-based compensation

 

3,687

 

 

 

692

 

 

 

 

 

 

 

Non-GAAP cash EBITDA

$

(10,954

)

 

$

(17,183

)

 

$

(29,154

)

 

$

(26,682

)

 

 

 

 

 

 

 

 

Non-GAAP
Adjusted Net Loss:

 

 

 

 

 

 

 

Net Loss

$

(13,161

)

 

$

(18,253

)

 

$

(28,834

)

 

$

(28,310

)

Adjustments:

 

 

 

 

 

 

 

Gain (loss) from change in fair value of derivative warrant liability

 

 

 

 

(43

)

 

 

(16

)

 

 

10

 

Total adjustments

 

 

 

 

(43

)

 

 

(16

)

 

 

10

 

Non-GAAP Net Income (Loss)

$

(13,161

)

 

$

(18,296

)

 

$

(28,850

)

 

$

(28,300

)

Non-GAAP adjusted net loss per share – basic and diluted

$

(0.06

)

 

$

(0.09

)

 

$

(0.14

)

 

$

(0.15

)

Weighted-average number of common shares outstanding – basic and diluted

 

209,809,994

 

 

 

198,137,420

 

 

 

205,889,651

 

 

 

190,892,223

 

 

 

 

 

 

 

 

 

Investor and Media Contact
+1 720-647-9605
IR@gevo.com

 


Release – 1-800-FLOWERS.COM, Inc. to Release Results for its Fiscal 2022 Fourth Quarter and Full Year on Thursday, September 1, 2022



1-800-FLOWERS.COM, Inc. to Release Results for its Fiscal 2022 Fourth Quarter and Full Year on Thursday, September 1, 2022

Research, News, and Market Data on 1-800-FLOWERS.COM

Aug 08, 2022

JERICHO, N.Y.–(BUSINESS WIRE)– 1-800-FLOWERS.COM, Inc. (NASDAQ: FLWS),a leading provider of gifts designed to help inspire customers to give more, connect more, and build more and better relationships, today announced that the Company will release financial results for its fiscal 2022 fourth quarter and full year (ended 7/3/22) on Thursday, September 1, 2022. The press release will be issued prior to market opening and will be followed by a conference call with members of senior management at 8:00 a.m. (ET).

 

The conference call will be available via live webcast from the Investor Relations section of the Company’s website at 1800flowersinc.com. A recording of the call will be posted on the website within two hours of the call’s completion. A telephonic replay of the call can be accessed beginning at 2:00 p.m. (ET) on September 1, 2022, through September 8, 2022, at: (US) 1-877-344-7529; (
Canada) 855-669-9658; (International) 1-412-317-0088; enter conference ID: #4688547. If you have any questions regarding the above information, please call the Investor Relations office at (516) 237-6131.

 

Special Note Regarding Forward-Looking Statements:
Some of the statements contained in the Company’s scheduled Thursday, September 1, 2022, press release and conference call regarding its results for its fiscal 2022 fourth quarter and full year (ended 7/3/22), other than statements of historical fact, may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the applicable statements. For a more detailed description of these and other risk factors, please refer to the Company’s SEC filings including its Annual Reports and Forms 10K and 10Q available at the Investor Relations section of the Company’s website at 1800flowersinc.com. The Company expressly disclaims any intent or obligation to update any of the forward-looking statements made in the scheduled conference call and any recordings thereof, or in any of its SEC filings, except as may be otherwise stated by the Company.

 

About 1-800-FLOWERS.COM,
Inc.

1-800-FLOWERS.COM, Inc. is a leading provider of gifts designed to help inspire customers to give more, connect more, and build more and better relationships. The Company’s e-commerce business platform features an all-star family of brands, including: 1-800-Flowers.com®, 1-800-Baskets.com®, Cheryl’s Cookies®, Harry & David®, PersonalizationMall.com®, Shari’s Berries®, FruitBouquets.com®, Moose Munch®, The Popcorn Factory®, Wolferman’s Bakery®, Vital Choice®, Stock Yards® and Simply Chocolate®. Through the Celebrations Passport® loyalty program, which provides members with free standard shipping and no service charge across our portfolio of brands, 1-800-FLOWERS.COM, Inc. strives to deepen relationships with customers. The Company also operates BloomNet®, an international floral and gift industry service provider offering a broad-range of products and services designed to help members grow their businesses profitably; Napco?, a resource for floral gifts and seasonal décor; DesignPac Gifts, LLC, a manufacturer of gift baskets and towers; and Alice’s Table®, a lifestyle business offering fully digital livestreaming floral, culinary and other experiences to guests across the country. 1-800-FLOWERS.COM, Inc. was recognized among the top 5 on the National Retail Federation’s 2021 Hot 25 Retailers list, which ranks the nation’s fastest-growing retail companies, and was named to the Fortune 1000 list in 2022. Shares in 1-800-FLOWERS.COM, Inc. are traded on the NASDAQ Global Select Market, ticker symbol: FLWS. For more information, visit 1800flowersinc.com or follow @1800FLOWERSInc on Twitter.

 

FLWS-COMP
FLWS-FN

Investor Contact:

Joseph D. Pititto

(516) 237-6131

invest@1800flowers.com

Media Contact:

Kathleen Waugh

(516) 237-6028

kwaugh@1800flowers.com

Source: 1-800-FLOWERS.COM, Inc

 


Release – Kratos Receives $20 Million Unmanned Aerial Drone System Production Contract



Kratos Receives $20 Million Unmanned Aerial Drone System Production Contract

Research, News, and Market Data on Kratos Defense & Security Solutions


SAN DIEGO, 
Aug. 08, 2022 (GLOBE NEWSWIRE) — 
Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has received an approximate 
$20 million production contract for high performance, jet powered, unmanned aerial target drone systems. Kratos is an industry leader in the development, design and fielding of affordable, high-performance jet powered unmanned aerial drone systems. The unmanned aerial drone systems produced under this contract award will be manufactured in a Kratos production facility. Due to competitive, security-related, and other considerations, no additional information will be provided related to this award.

Steve Fendley, President of Kratos Unmanned Systems Division, said, “We believe that this contract award is representative of Kratos’ industry leading position for certain of the highest performance and most capable jet drone aircraft flying in the world today. Kratos today has multiple active production lines producing approximately 150 target and tactical jet drone aircraft annually, and this new target drone production contract award is a key element of our future expected growth trajectory.”

About Kratos
Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to 
www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended 
December 26, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the 
SEC by Kratos.

Press Contact: Yolanda White 858-812-7302 Direct

Investor Information:
877-934-4687

investor@kratosdefense.com

 


Release – Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344



Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Research, News, and Market Data on Cocrystal Pharma

BOTHELL, Wash., Aug. 08, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces it has engaged hVIVO, a subsidiary of London-based Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organization (CRO), to conduct a Phase 2a clinical trial with the Company’s novel, broad-spectrum, orally administered antiviral candidate CC-42344. This candidate represents a new class of investigational medicine designed to directly inhibit replication of the virus for the treatment of pandemic and seasonal influenza A.

“We are highly encouraged by the Phase 1 healthy volunteer trial results received so far and are committed to rapidly advancing this program into a human challenge Phase 2a trial in influenza A-infected subjects,” said Sam Lee, Ph.D., Cocrystal’s President and co-interim CEO. “The fact that influenza virus is constantly mutating against existing influenza antiviral drugs elevates an urgent need for effective antiviral therapeutics. CC-42344 is a broad-spectrum oral PB2 inhibitor that is highly active against drug-resistant influenza A strains. Further clinical development of CC-42344 offers an opportunity to address the need. Open Orphan is a world leader in conducting human challenge clinical trials with antiviral drug candidates, making it an ideal partner for conducting our Phase 2a trial.”

The single-center, double-blind, placebo-controlled Phase 2a human challenge trial is designed to evaluate safety, viral and clinical measures of orally administered 
CC-42344 to subjects challenged with influenza A. The trial is expected to be initiated in the second half of 2023, pending approval from the United Kingdom Medicines and Healthcare Products Regulatory Agency. This study will be conducted at hVIVO’s state-of-the-art facility in the United Kingdom.

Yamin “Mo” Khan, Open Orphan CEO, said, “We are pleased to be working with Cocrystal to evaluate its promising antiviral drug candidate for influenza A. A human challenge trial is an excellent option for Cocrystal, as it can rapidly provide efficacy data at a lower cost than traditional field trials.”

Cocrystal is conducting a Phase 1 study with CC-42344 in healthy subjects in Australia. The Company recently announced pharmacokinetic (PK) data supporting once-daily dosing from the single-ascending dose portion of this study. Enrollment in the multiple-ascending dose portion of the Phase 1 trial is ongoing, with full trial results expected in 2022.

About CC-42344 and
Influenza

CC-42344 is an oral PB2 inhibitor that blocks an essential step of viral replication. CC-42344 was discovered using Cocrystal’s proprietary structure-based drug discovery platform technology. It is specifically designed to be effective against all significant pandemic and seasonal influenza A strains and to have a high barrier to resistance due to the way the virus’ replication machinery is targeted. 
CC-42344 targets the influenza polymerase, an essential replication enzyme with several highly essential regions common to multiple influenza strains, including pandemic strains. In
vitro 
testing showed CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu® and Xofluza®, while also demonstrating favorable pharmacokinetic and safety profiles.

The global influenza therapeutics market is projected to reach $9.5 billion by 2027, from $6.6 billion in 2020, growing at a 4.8% CAGR between 2021 and 2027, according to a report published by Precision Reports in June 2022.

About hVIVO and
Open Orphan plc

hVIVO, a subsidiary of Open Orphan plc, is a rapidly growing specialist contract research organization (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and longstanding client base of biopharma companies.

About Cocrystal
Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cocrystal Pharma Cautionary
Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our collaboration with hVIVO to conduct a Phase 2a clinical trial for CC-42344 and the anticipated timeline for the study, the potential design and efficacy of CC-42344, and the demand for products designed to treat influenza and opportunities presented thereby. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the availability of federal government funding and budgetary issues that may arise, the risks and uncertainties arising from any future impact of the COVID-19 pandemic including in Australia, the Russian invasion of Ukraine, and/or inflation and Federal Reserve interest rate increases in response thereto on the global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs such as obtaining the requisite regulatory approvals including from the United Kingdom Medicines and Healthcare Products Regulatory Agency, the ability of the CRO to recruit patients into clinical trials, and the results of the studies for CC-42344. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100

jcain@lhai.com

Media Contact:
JQA Partners
Jules Abraham
917-885-7378

Jabraham@jqapartners.com

# # #


Primary Logo

Source: Cocrystal Pharma, Inc.

Released August 8,
2022

 


Release – Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights



Tonix Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

Research, News, and Market Data on Tonix Pharmaceuticals

Phase 1 Study
of TNX-801, a Vaccine in Development for the Prevention of Monkeypox and
Smallpox, Expected to Initiate in First Half 2023 in Kenya; the U.S. has
Declared Monkeypox a Public Health Emergency

U.S. National Institute of Drug
Abuse (NIDA) Grant Awarded for the Development of TNX-1300 for Cocaine
Intoxication; Phase 2 Study of TNX-1300 Expected to Initiate in Fourth Quarter
2022

Advanced Development Center in
Dartmouth, Mass. is Open and Expected to Imminently Conduct Process Development
and Clinical Trial Manufacturing of Live-Virus Vaccines

Cash and Cash Equivalents
Totaled Approximately $145 Million at June 30, 2022

CHATHAM, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2022, and provided an overview of recent operational highlights.

“The rapidly expanding outbreaks of monkeypox in the U.S. and approximately 80 other countries outside of Africa have brought attention to our work on a novel monkeypox vaccine, TNX-801, which has already been shown to protect non-human primates against a challenge with lethal doses of monkeypox. The U.S. has declared monkeypox a public health emergency. In addition, we are excited by the many opportunities ahead for our pipeline of CNS, rare disease, immunology and infectious disease product candidates,” said Seth Lederman, M.D., Chief Executive Officer of Tonix. “We are on track to have four CNS programs in the clinic by the end of 2022, including our most advanced program, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia, which is in mid-Phase 3 development, Phase 2 studies of TNX-102 SL for Long COVID and PTSD and a Phase 2 study of TNX-1300 for cocaine intoxication.”

Recent
Highlights—Key Product Candidates*

Infectious
Disease Pipeline

TNX-801 (live
horsepox virus vaccine for percutaneous administration): vaccine against
smallpox and monkeypox designed as a single-administration vaccine to elicit T
cell immunity

  • In July 2022, Tonix announced a collaboration with the Kenya Medical Research Institute (KEMRI) to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop TNX-801 as a vaccine to protect against monkeypox and smallpox. The study is expected to start in the first half of 2023.
  • Tonix presented data from a research collaboration with The University of Alberta in a poster presentation at the 4th Symposium of the Canadian Society for Virology. The poster titled, “Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox,” describes data from animals vaccinated with TNX-801 to protect against monkeypox. The poster presentation reports that all animals (n=8) vaccinated with TNX-801 were fully protected with sterilizing immunity from a challenge with intra-tracheal monkeypox. The vaccinations with TNX-801 were well tolerated. Synthetic horsepox virus is the basis for the Company’s TNX-801 vaccine in development to protect against monkeypox and smallpox and for the Company’s Recombinant Pox Virus (RPV) platform to protect against other pathogens, including SARS-CoV-2.
  • Tonix announced the issuance of U.S. Patent for TNX-801 smallpox and monkeypox vaccine and Recombinant Pox Virus (RPV) platform technology. This patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.

TNX-1850 (live
virus vaccine based on Tonix’s recombinant pox virus vector): COVID-19 vaccine
designed as single-administration vaccine to elicit T cell immunity

  • Tonix announced the issuance of U.S. Patent for TNX-801 smallpox and monkeypox vaccine and Recombinant Pox Virus (RPV) platform technology (TNX-1850). This patent is expected to provide Tonix with U.S. market exclusivity until 2037, excluding any possible patent term extensions or patent term adjustments.

TNX-2300: Live
virus vaccine based on a bovine parainfluenza virus vector to protect against
COVID-19

  • In April 2022, Tonix extended a sponsored research agreement with Kansas State University to develop a vaccine candidate, TNX-2300, for the prevention of COVID-19 that utilizes a novel live virus vaccine vector platform based on bovine parainfluenza virus. The efficacy of co-expression of the CD40-ligand, also known as CD154, to stimulate T cell immunity will also be tested.
  • Attenuated bovine parainfluenza virus has previously been shown to be an effective antigen delivery vector in humans. Notably and most importantly, following extensive testing in non-human primates, the attenuated BPI3V was shown to be well tolerated, infectious, immunogenic, and stable in infants and children. The vector is well suited for mucosal immunization using a nasal atomizer, but it can also be delivered parenterally.

Central
Nervous System (CNS) Pipeline

TNX-102 SL
(cyclobenzaprine HCl sublingual tablet): small molecule for the management of
fibromyalgia (FM)

  • Enrollment continues in the RESILIENT study, a double-blind, randomized, placebo-controlled, potentially pivotal Phase 3 study of TNX-102 SL for the management of fibromyalgia. The two-arm trial is expected to enroll approximately 470 participants in the U.S. Results from a planned interim analysis are expected in the first quarter of 2023.

TNX-102 SL for
the treatment of Long COVID, also known as Post-Acute Sequelae of COVID-19
(PASC)

  • The Company continues to expect to start a Phase 2 clinical study with TNX-102 SL as a potential treatment for a subset of patients with Long COVID with multi-site pain in the third quarter of 2022.
  • As previously announced, the results of a retrospective observational database study of over 50,000 adult U.S. patients with Long COVID showed that over 40% of patients had fibromyalgia-like multi-site pain. These findings support the feasibility of the planned Phase 2 study which will enroll Long COVID patients with multi-site pain.

TNX-102 SL for
the treatment of Posttraumatic Stress Disorder (PTSD)

  • Tonix expects to begin enrolling a Phase 2 study of TNX-102 SL in police in Kenya in the third quarter of 2022.

TNX-1300
(recombinant double mutant cocaine esterase): biologic for life-threatening
cocaine intoxication

  • In August 2022, Tonix announced that it received a Cooperative Agreement grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to support development of TNX-1300.
  • The Company expects to initiate a new Phase 2 clinical study of TNX-1300 for the treatment of cocaine intoxication in the fourth quarter of 2022, pending agreement with the U.S. Food and Drug Administration (FDA). The Phase 2 trial, which has the potential to be a pivotal study, is a single-blind, open-label, placebo-controlled, randomized study comparing the safety of a single 200 mg dose of TNX-1300 to standard of care alone in approximately 60 emergency department patients presenting with cocaine intoxication.
  • A positive Phase 2a study of volunteer cocaine users in a controlled laboratory setting has been previously completed. TNX-1300 has been granted Breakthrough Therapy designation by the FDA.

TNX-1900
(intranasal potentiated oxytocin): small peptide for migraine, craniofacial
pain, insulin resistance and related disorders, and obesity associated binge
eating disorder

  • Tonix announced that U.S. Patent 11,389,473 issued in July 2022. The patent, entitled “Magnesium-Containing Oxytocin Formulations and Methods of Use” claims methods and compositions for treating pain, including migraine headaches, using intranasal magnesium-containing oxytocin formulations. This patent, excluding possible patent term extensions, is expected to provide Tonix with U.S. market exclusivity until January 2036.
  • Tonix announced the publication of a paper, entitled “Impact of Magnesium on Oxytocin Receptor Function,” in the journal Pharmaceutics, that described results from a research team led by Professor David Yeomans. The paper includes data showing the enhancing effects of magnesium (Mg2+) on the activity of intranasal oxytocin in an animal model of craniofacial pain. The Mg2+ potentiated formulation of intranasal oxytocin is the basis for the Company’s TNX-1900 drug candidate in development to prevent migraine headaches in chronic migraineurs. Professor Yeomans was the scientific founder of Trigemina, Inc. from which Tonix acquired rights to the Mg2+potentiated oxytocin technology. The potential clinical significance of these observations is that the formulation of oxytocin plus Mg2+ in Tonix’s TNX-1900 has the potential to enhance oxytocin efficacy for pain as well as for other uses.
  • The Company expects to begin enrollment in a Phase 2 study of TNX-1900 for the prevention of migraine headache in chronic migraineurs the first half of 2023.

TNX-601 ER
(tianeptine hemioxalate extended-release tablets): small molecule for the
treatment of major depressive disorder (MDD), PTSD, and neurocognitive
dysfunction associated with corticosteroid use.

  • In July 2022, Tonix announced development of a new extended release formulation of TNX-601, for the treatment of MDD. Tonix expects to initiate a Phase 2 study of TNX-601 ER for the treatment of MDD in the first quarter of 2023, pending FDA clearance of its Investigational New Drug (IND) application.

Rare Disease
Pipeline

TNX-2900
(intranasal potentiated oxytocin): small peptide for the treatment of
Prader-Willi syndrome (PWS)

  • Tonix delivered a presentation titled, “TNX-2900 (Intranasal Oxytocin + Magnesium) in Development for the Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome” at the World Orphan Drug Congress USA in July 2022.
  • TNX-2900 has received Orphan Drug designation from the FDA for the treatment of PWS.

Immunology
Pipeline

TNX-1500
(anti-CD40L monoclonal antibody): third generation monoclonal antibody for
prophylaxis of organ transplant rejection and treatment of autoimmune
disorders.

      *All of
Tonix’s product candidates are investigational new drugs or biologics and have
not been approved for any indication.

Recent
Highlights—Facilities and Corporate

  • In July 2022, Tonix announced the appointment of Sina Bavari, Ph.D. as Executive Vice President, Infectious Disease Research and Development. In this role, Dr. Bavari will be responsible for leading Tonix’s development of its growing infectious disease pipeline and will serve as a key member of the Company’s executive leadership team.
  • In June 2022, Tonix held a ribbon-cutting ceremony for its Advanced Development Center (ADC) located in the New Bedford Business Park in North Dartmouth, Massachusetts. The new facility is designed for accelerated research, development and analytical capabilities, as well as the production of clinical trial quality vaccines for infectious diseases, including monkeypox, smallpox and COVID-19 as well as other infectious diseases for pandemic preparedness. The ADC is open and expected to soon perform process development and clinical trial manufacturing of live-virus vaccines.

Recent
Highlights–Financial

As of June 30, 2022, Tonix had $145.5 million of cash and cash equivalents, compared to $178.7 million as of December 31, 2021. In June 2022, Tonix issued 2,500,000 shares of Series A convertible redeemable preferred stock and 500,000 shares of Series B convertible redeemable preferred stock to certain institutional investors in a private placement for gross proceeds of $28.5 million. The Company expects to use the proceeds to redeem the preferred stock.

Cash used in operations was approximately $21.2 million for the three months ended June 30, 2022, compared to $19.1 million for the same period in 2021. Capital expenditures were approximately $14.4 million for the three months ending June 30, 2022 compared to $1.4 million for the same period in 2021. The increase was primarily due to the continued buildout of the ADC in North Dartmouth, Mass.

Second Quarter 2022 Financial Results

Research and development (R&D) expenses for the three months ended June 30, 2022 were $16.6 million, compared to $18.1 million for the same period in 2021. The decrease is predominately due to decreased non-clinical expenses, offset by an increase in employee-related expenses. We continue to expect R&D expenses to increase during 2022 as we move our clinical development programs forward and invest in our development pipeline.

General and administrative (G&A) expenses for the three months ended June 30, 2022 were $6.8 million, compared to $5.4 million for the same period in 2021. The increase is primarily due to employee-related expenses.

Net loss available to common stockholders was $27.4 million, or $1.22 per share, basic and diluted, for the three months ended June 30, 2022, compared to net loss of $23.6 million, or $2.25 per share, basic and diluted, for the same period in 2021. The basic and diluted weighted average common shares outstanding for the three months ended June 30, 2022 was 22,404,371, compared to 10,483,112 shares for the same period in 2021.

About Tonix
Pharmaceuticals Holding Corp.
*

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the first quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the third quarter of 2022. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication that is Phase 2 ready and has been granted Breakthrough Therapy designation by the FDA. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the first half of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the first half of 2023. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the first half of 2023. Tonix’s lead vaccine candidate for COVID-19 is TNX-1850, a live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform. A Phase 1 study of the COVID-19 vaccine is expected to be initiated in the second half of 2023.

*All of Tonix’s product candidates are investigational
new drugs or biologics and have not been approved for any indication.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward
Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.


TONIX PHARMACEUTICALS HOLDING
CORP.

CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS

(In
Thousands, Except Share and Per Share Amounts)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

COSTS AND EXPENSES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

16,579

 

 

$

18,133

 

 

$

35,001

 

 

$

33,460

 

General and administrative

 

 

6,757

 

 

 

5,429

 

 

 

14,771

 

 

 

10,838

 

 

 

 

23,336

 

 

 

23,562

 

 

 

49,772

 

 

 

44,298

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Loss

 

 

(23,336

)

 

 

(23.562

)

 

 

(49,772

)

 

 

(44,298

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest and other income, net

 

 

196

 

 

 

9

 

 

 

215

 

 

 

92

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(23,140

)

 

 

(23,553

)

 

 

(49,557

)

 

 

(44,206

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock deemed dividend

 

 

4,255

 

 

 

 

 

 

4,255

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss available to common stockholders

 

$

(27,395

)

 

$

(23,553

)

 

$

(53,812

)

 

$

(44,206

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per common share, basic and diluted

 

$

(1.22

)

 

$

(2.25

)

 

$

(2.76

)

 

$

(4.49

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding, basic and diluted

 

 

22,404,371

 

 

 

10,483,112

 

 

 

19,462,280

 

 

 

9,843,309

 


TONIX PHARMACEUTICALS HOLDING
CORP.

CONDENSED
CONSOLIDATED BALANCE SHEETS

(In
Thousands)

(Unaudited)

 

June 30, 2022

 

December 31, 20211

Assets

 

 

Cash and cash equivalents

$

145,478

 

$

178,660

Restricted cash

 

31,500

 

—–

Prepaid expenses and other

 

14,769

 

 

10,389

Total current assets

 

191,747

 

 

189,049

Other non-current assets

 

84,418

 

 

51 ,851

Total assets

$

276,165

 

$

240,900

 

 

 

Liabilities and stockholders’ equity

 

 

Total liabilities

$

16,383

 

$

22,183

Temporary equity

 

31,500

 

 

Stockholders’ equity

 

228,282

 

 

218,717

Total liabilities and stockholders’ equity

$

276,165

 

$

240,900

1The condensed consolidated balance sheet for the year ended December 31, 2021 has been derived from the audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.

Contacts

Jessica Morris
(corporate)

Tonix Pharmaceuticals
investor.relations@tonixpharma.com

(862) 799-8599

Olipriya Das,
Ph.D. (media)

Russo Partners
Olipriya.Das@russopartnersllc.com

(646) 942-5588

Peter Vozzo
(investors)

ICR Westwicke
peter.vozzo@westwicke.com

(443) 213-0505

 


Source: Tonix Pharmaceuticals Holding Corp.

Released
August 8, 2022


Uranium Investments and The Inflation Reduction Act



Image Credit: Johannes Plenio (Pexels)


Uranium is Reacting to Increasing Demand in the U.S. with Increased Support from Washington

The Senate approved Inflation Reduction Act (IRA) is yet another nod to nuclear energy. As the world is coming around to the idea that a significant, non-weather-dependent energy source is needed, if there is to be a successful transition away from fossil fuels, nuclear, more specifically, uranium fueled power, continues to get the nod from the U.S. Department of Energy (DOE), lawmakers in Washington, green energy groups, and even from countries like Japan and Germany. 

This IRA bill that just passed in the Senate is headed to the House with almost $400 billion in energy security and climate-related programs over the next ten years. It is expected to easily pass without much renegotiation between the two branches of Congress. Below are some specifics on how it will impact the nuclear energy industry and, therefore, uranium investments. 

 

Enriched Tax Credits for Nuclear Energy

There is a provision that improves upon the Zero-Emissions Nuclear Production law, which is a Power Tax Credit specific for nuclear energy producers. It is in the form of a scaled credit based on plant revenue and applies to existing power plants. The program now includes nuclear and would begin in 2024 and end in 2032; it will offer 5x the benefit if labor requirements are adhered to. The 2032 deadline is an extension of the original plan, which was included in Build Back Better.

The IRA provides for a technology-neutral clean energy production credit of 0.3 cents * kWh base rate for ten years starting in 2025. New, to the program is that energy producers (including coal) will receive a 10% credit in addition to any clean energy credit. This benefit does not look at the technology that is producing the energy.

 

High-Assay Low Enrichment Uranium (HALEU)

The version that passed the Senate also includes $700 million for HALEU, which is the fuel expected to be used in the next generation of reactors. This is interesting in that HALEU production is limited to Russia.

The HALEU funding is broken down into three categories and references the Energy Act of 2020:

  • $100M: Licensing and regulation of facilities and transportation packages.
  • $500M: Acquiring or providing HALEU from a stockpile of uranium to produce HALEU, estimating the quantity of HALEU necessary for domestic, commercial use, and developing a consortium to support the availability of HALEU for civilian use.
  • $100M: Support the availability of HALEU for civilian domestic research, development, demonstration, and commercial.


DOE Loans

The bill also includes $250 billion for DOE loans. The loans will help provide funding to smooth the road toward building tomorrow’s carbon-free technology currently in development.

 

Related Investments

There are many non-energy generating U.S. companies involved in the various areas of providing nuclear fuel and even storing spent fuel. Additionally, there is a futures market and ETFs that either work to mimic the price changes in U308 or own uranium outright and store and provide valuation on the trust.


Source: Pennsylvania
State University Radiation Science and Engineering Center (Public Domain)

The chart below is provided as an example of how companies involved in producing uranium, uranium futures, and the ETF that owns the mineral all trade in relation to each other (three-month period).

Energy Fuels (UUUU) is the largest uranium producer in the U.S. and holds more production capacity and uranium resources than any other U.S. producer. A new research report update on Energy Fuels by Noble Capital Markets was released today (August 8). Read it here.


Source: Koyfin

enCore Energy Corp. (ENCUF) is focused on becoming a domestic (USA) uranium producer. It has significant existing resources in the southwest United States and licensed uranium production facilities in Texas; encore holds the largest uranium position in the Grants Mineral Belt and licensed processing capacity to respond quickly to market opportunities. Discover more here.

Peninsula Energy Ltd (PENMF) is a uranium mining and development company. Projects include Lance ISR Uranium Projects located on the north-east flank of the Powder River Basin in Wyoming and Karoo Uranium Projects in South Africa. It has three reportable operating segments, Lance uranium projects, Wyoming USA; Karoo uranium projects, South Africa; and Corporate. More data on Peninsula Energy is available here, and in the video link below.


Take Away

The provisions in the Inflation Reduction Bill, which seems sure to pass the House and be signed into law, would seem to create a tailwind worth several hundred billion to the industry. It also serves as a glowing nod toward nuclear as one important piece to meeting reduced carbon emissions goals.

The IRA bill gives current investors in the related nuclear power and uranium industries a reason to be more bullish and newer investors a reason to react to the possibility of adding stocks of producers, futures contracts, or uranium itself into their portfolios.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Energy and Global Fundamentals Make a Good Case for Owning Western Uranium Stocks



Can You Invest in Uranium Directly?




Peninsula Energy (PENMF) NobleCon18 – Presentation Replay



Energy Fuels (UUUU) NobleCon18 – Presentation Replay

Sources

 

https://www.eia.gov/energyexplained/nuclear/the-nuclear-fuel-cycle.php

https://www.eia.gov/todayinenergy/detail.php?id=51978

https://thebreakthrough.org/articles/advancing-nuclear-energy-report

https://www.whitehouse.gov/wp-content/uploads/2022/08/SAP-H.R.-5376.pdf


Stay up to date. Follow us:

 

A Look at Global Inflation and its Causes


Image Credit: Viv Lynch (Flickr)


Inflation is Spiking Around the World – Not Just in the United States

The 9.1% increase in U.S. consumer prices in the 12 months ending in June 2022, the highest in four decades, has prompted many sobering headlines.

Meanwhile, annual inflation in Germany and the U.K. – countries with comparable economies – ran nearly as high: 7.5% and 8.2%, respectively, for the 12 months ending in June 2022. In Spain, inflation has hit 10%.

It might seem like U.S. policies brought on this predicament, but economists like me doubt it because inflation is spiking everywhere, with few exceptions. Rates averaged 9.65% in the 38 largely wealthy countries that belong to the Organization for Economic Cooperation and Development through May 2022.

What revved up those price increases starting in early 2021?

Scarcity Put Pressure on Prices Everywhere

When the COVID-19 pandemic began, demand for computers and other high-tech goods soared as many people switched from working in offices to clocking in at home.

Computer chip manufacturers struggled to keep up, leading to chip shortages and higher prices for a dizzying array of devices and machines requiring them, including refrigerators, cars and smartphones.

It’s not just chips. Many of the goods Americans consume, such as cars, televisions and prescription drugs, are imported from all corners of the world.

This article was republished with
permission from The Conversation, a news site dedicated to sharing ideas from
academic experts. It was written by and represents the research-based opinions
of Christopher Decker, Professor of Economics, University of Nebraska Omaha.

Supply Chain Strains

On top of problems tied to supply and demand changes, there have been major disruptions to how goods move to manufacturers and then onto consumers along what’s known as the supply chain.

Freight disruption, whether by ship, train or truck, has interfered with the delivery of all sorts of goods since 2020. That’s caused the cost of shipping goods to rise sharply.

These massive shipping disruptions have exposed the disadvantages of the popular just-in-time practice for managing inventory.

By keeping as little of the materials needed to make their products on hand, companies become more vulnerable to shortages and transportation snafus. And when manufacturers are unable to make their products quickly, shortages occur and prices surge.

This approach, especially when it involves the reliance on far-flung suppliers, has left businesses much more susceptible to market shocks.

 

Labor Complications

The beginning of the pandemic also sent shock waves through labor markets with lasting effects.

Many businesses either fired or furloughed large numbers of workers in 2020. When governments began to relax restrictions related to the pandemic, many employers found that significant numbers of their former workers were unwilling to return to work.

Whether those workers had chosen to retire early, seek new jobs offering a better work-life balance or become disabled, the results were the same: labor shortages that required higher wages to recruit replacements and retain other employees.

Again, all of these dynamics are occurring globally, not just in the U.S.

War in Ukraine compounded these woes

Russia’s war on Ukraine, which began officially on Feb. 24, 2022, has also exacerbated inflation by interfering with the global supply of fuels and grains.

The conflict’s effects are reverberating around the globe and fueling inflation.

Russia is the world’s second-largest exporter of crude oil. Sanctions against Russian imports, combined with Russia halting oil shipments to European countries in retaliation, has led to disruptions in the global oil market.

As Europe buys more oil from the Middle East, demand for oil from that region increases, prompting price increases. Crude prices jumped from $101 per barrel in late February 2022, to $123 a month later. Prices stayed high for several months but by late July were around $100 a barrel again.

Food prices have increased substantially in the U.S. and elsewhere, partly due to this conflict. Ukraine possesses some of the most fertile soil in the world and is the third-largest exporter of corn.

Russia’s destruction of Ukrainian crops and its blockade of Ukrainian exports have led to significant price increases worldwide for agricultural commodities.


How Will the World Respond?

Support for globalization and international trade has waned in recent years. Given supply chain disruptions and the war in Ukraine fueling inflation, this trend will likely continue.

However, as an economist, I believe the benefits of free and open trade still outweigh current challenges.

In my view, there isn’t anything fundamentally wrong with the globalization that cannot be fixed. But, like quelling inflation and alleviating supply chain bottlenecks, it will take time.


Suggested Content



Fewer Quitters and Fewer Job Openings Suggest a Move Toward Normalcy



What Might be in a Portfolio Allocated for a Republican Majority in the House?





Useful Information on Where CPI Numbers Come From



Powell is Told by President that He is the Face of Inflation

Stay up to date. Follow us:

 

Release – ACCO Brands Posts Solid Quarterly Results in Challenging Operating Environment



ACCO Brands Posts Solid Quarterly Results in Challenging Operating Environment

Research, News, and Market Data on ACCO Brands

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced its second quarter results for the period ended June 30, 2022.

  • Net sales were $521.0 million, up 0.6 percent; comparable sales were up 5.2 percent
  • EPS was $0.40 versus $0.50 in 2021; adjusted EPS was $0.37 versus $0.43 in 2021
  • Continued sales momentum in North America driven by strong back-to-school sell-in
  • Continued recovery in International segment, led by growth in Brazil and Mexico
  • Updated guidance reflecting a more conservative view of the macroeconomic environment

“We posted impressive comparable sales with growth across all operating segments and multiple product categories, led by our Five Star® and Kensington® brands, and in our Latin American business. We have achieved five consecutive quarters of sustained comparable sales growth and remain confident in our strategy of transforming our Company towards more consumer-oriented products. Our performance continues to demonstrate the benefits of our geographic diversity and balance and skillful execution by our employees. Our second quarter proved to be more challenging than originally anticipated mainly due to slower economic growth, increased inflation and unfavorable foreign currency impacts, but additional price increases to counter inflation leave us well-positioned for second half margin expansion, with rates greater than the prior year,” said Boris Elisman, Chairman and Chief Executive Officer of ACCO Brands.

Second Quarter Results

Net sales increased 0.6 percent to $521.0 million from $517.8 million in 2021. Comparable sales increased 5.2 percent. Both reported and comparable sales were driven by higher prices, as strong volume of school products, computer accessories, and business products was offset by lower sales of gaming accessories. Adverse foreign exchange reduced sales $23.6 million, or 4.6 percent.

Operating income increased to $55.4 million versus $49.9 million in 2021 due to a favorable change related to the contingent earnout partially offset by higher restructuring expense of $1.9 million. Operating income this year included contingent earnout income of $9.4 million compared with contingent earnout expense of $4.9 million in the prior year. Adjusted operating income decreased to $58.1 million compared with $67.2 million in the prior year, due to higher inflation that was not fully mitigated with price increases, lower volume and adverse foreign exchange of $1.0 million, partially offset by lower incentive compensation expense.

The Company reported net income of $39.4 million, or $0.40 per share, compared with net income of $48.6 million, or $0.50 per share, last year. Net income declined in 2022 from lower discrete tax benefits as well as reduced Brazil operating tax credits. This decline was partially offset by improved operating income as noted above. Adjusted net income was $36.0 million compared with $42.0 million in 2021, aligned with the adjusted operating income decline. Adjusted earnings per share were $0.37 compared with $0.43 in 2021.

Business Segment
Results

ACCO Brands North America – Sales of $306.6 million increased 3.9 percent from $295.1 million in 2021 and comparable sales increased 4.4 percent to $308.0 million. The increases in both were primarily due to higher prices and volume increases in school products, computer accessories, and business products, partially offset by lower sales of gaming accessories.

Operating income was $50.7 million versus $53.8 million in 2021. Adjusted operating income of $57.2 million decreased from $59.9 million in 2021. The decreases in operating income and adjusted operating income were primarily due to lower gross margins as inflation more than offset the benefit of price increases and lower SG&A. The current period included $0.8 million of higher restructuring costs.

ACCO Brands EMEA – Sales of $137.9 million decreased 12.2 percent from $157.0 million in 2021, due to adverse foreign exchange of $19.8 million, or 12.6 percent. Comparable sales of $157.7 million increased 0.4 percent as price increases offset lower volume in a difficult economic environment that included accelerated inflation.

The segment posted an operating loss of $1.5 million compared with operating income of $9.9 million in 2021 due to inflation that exceeded the benefit of price increases and lower volume. Adjusted operating income was $2.1 million, down from $13.8 million in 2021 for the same reasons. Cost increases in EMEA have been higher than in other segments due to significant increases in locally sourced raw materials related to the war in Ukraine, as well as high energy costs.

ACCO Brands International – Sales of $76.5 million increased 16.4 percent from $65.7 million in 2021 due to higher prices and increased volume, primarily in Latin America from a return to in-person education. Adverse foreign exchange was $2.4 million. Comparable sales were $78.9 million, up 20.1 percent, for the same reasons.

Operating income of $6.3 million increased from $2.8 million in 2021 due to higher sales and good expense management, partially offset by inflation. Adjusted operating income of $8.6 million increased from $4.8 million due to those same factors.

Six Month Results

Net sales increased 3.7 percent to $962.6 million from $928.3 million in 2021 as higher prices more than offset the unfavorable impact of foreign exchange which reduced sales by $38.5 million, or 4.1 percent. Comparable sales increased 7.8 percent due to higher prices and volume as offices and schools began reopening for in-person activity, partially offset by lower sales of gaming accessories.

Operating income increased to $62.2 million from $48.8 million in 2021, due to a favorable change of $18.4 million related to the contingent earnout, partially offset by the reduction of other adjusting items. Adjusted operating income was $80.7 million compared with $91.8 million last year primarily due to inflation that exceeded the benefit of price increases, partially offset by reduced incentive compensation expense. Unfavorable foreign exchange reduced operating income $2.2 million.

Net income was $36.7 million, or $0.37 per share, compared with $28.2 million, or $0.29 per share, in 2021, aligned with the operating income increase. Prior year net income included two significant discrete tax items, as well as expenses related to debt refinancing which did not repeat in 2022. Adjusted net income was $46.4 million, compared with $52.0 million in 2021, primarily reflecting the adjusted operating income decline, partially offset by lower interest expense. Adjusted earnings per share were $0.47 compared with $0.54 in 2021.

Capital Allocation and
Dividend

Year to date, the Company had $97.9 million of net cash outflow from operating activities. Free cash flow of $95.5 million represents cash used from operating activities of $97.9 million, excluding cash payments made for the PowerA contingent earnout of $9.2 million, less cash used for additions to property, plant and equipment of $7.0 million, plus cash proceeds from the disposition of assets of $0.2 million. The Company paid $14.4 million in dividends and repurchased 2.7 million shares for $19.4 million.

ACCO Brands today announced that its board of directors declared a regular quarterly cash dividend of $0.075 per share. The dividend will be paid on September 20, 2022, to stockholders of record as of the close of business on August 26, 2022.

Full Year 2022 Outlook

The Company is providing an updated full year outlook to reflect a more conservative view for the remainder of the year, including a moderating demand environment, continuing cost inflation, and more adverse foreign exchange. However, the Company anticipates second half gross margin improvement with rates higher than the prior year, as its pricing actions should begin to mitigate the impact of cumulative cost increases.

“Our company has a proven track record of managing well in periods of economic uncertainty and increasing our competitive advantage. We believe we have the right strategy and are well positioned to continue to deliver organic sales growth, compelling market performance, and improved financial results in the second half of this year and beyond,” Elisman added.

 

 

 

 

 

 

 

 

Current

Mid-Point

Prior

Mid-Point

Comparable Net Sales Growth

 

4.0% to 6.0%

5.0 %

3.5% to 8.5%

6.0%

FX Impact on Net Sales (1)

 

(4.5)%

 

(2.5)%

 

Reported Net Sales Growth

 

(0.5)% to 1.5%

0.5 %

1.0% to 6.0%

3.5%

Comparable Adjusted EPS

 

$1.45 to $1.50

$1.48

$1.52 to $1.62

$1.57

FX impact on Adjusted EPS (1)

 

$(0.06)

 

$(0.04)

 

Adjusted EPS

 

$1.39 to $1.44

$1.42

$1.48 to $1.58

$1.53

Free Cash Flow

 

$135M to $150M

$142.5

$165M

 

Adjusted Tax Rate

 

Approximately 29%

 

Approximately 29%

 

Bank Net Leverage

 

Approximately 3.0x

 

Less than 3.0x

 

(1) Based on spot rates as of 7/19/2022

Webcast

At 8:30 a.m. EDT on August 9, 2022, ACCO Brands Corporation will host a conference call to discuss the Company’s second quarter 2022 results. The call will be broadcast live via webcast. The webcast can be accessed through the Investor Relations section of www.accobrands.com. The webcast will be in listen-only mode and will be available for replay following the event.

About ACCO Brands
Corporation

ACCO Brands, the Home of Great Brands Built by Great People, designs, manufactures and markets consumer and end-user products that help people work, learn, play and thrive. Our widely recognized brands include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found at www.accobrands.com.

Non-GAAP Financial
Measures

In addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this earnings release to aid investors in understanding the Company’s performance. Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the “About Non-GAAP Financial Measures” section of this earnings release.

Forward-Looking
Statements

Statements contained in this earnings release, other than statements of historical fact, particularly those anticipating future financial performance, business prospects, growth, strategies, business operations and similar matters, results of operations, liquidity and financial condition, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of management based on information available to us at the time such statements are made. These statements, which are generally identifiable by the use of the words “will,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “forecast,” “project,” “plan,” and similar expressions, are subject to certain risks and uncertainties, are made as of the date hereof, and we undertake no duty or obligation to update them. Because actual results may differ materially from those suggested or implied by such forward-looking statements, you should not place undue reliance on them when deciding whether to buy, sell or hold the Company’s securities.

Our outlook is based on certain assumptions, which we believe to be reasonable under the circumstances. These include, without limitation, assumptions regarding both the near-term and long-term impact of the COVID-19 pandemic; inflation and the impact on demand of global economic uncertainties; changes in the competitive landscape, including ongoing uncertainties in the traditional office products channels; as well as the impact of fluctuations in foreign currency and acquisitions and the other factors described below.

Among the factors that could cause our actual results to differ materially from our forward-looking statements are: the ongoing impact of the COVID-19 pandemic; a relatively limited number of large customers account for a significant percentage of our sales; issues that influence customer and consumer discretionary spending during periods of economic uncertainty or weakness; risks associated with foreign currency fluctuations; challenges related to the highly competitive business environment in which we operate; our ability to develop and market innovative products that meet consumer demands and to expand into new and adjacent product categories that are experiencing higher growth rates; our ability to successfully expand our business in emerging markets and the exposure to greater financial, operational, regulatory, compliance and other risks in such markets; the continued decline in the use of certain of our products; risks associated with seasonality; the sufficiency of investment returns on pension assets, risks related to actuarial assumptions, changes in government regulations and changes in the unfunded liabilities of a multi-employer pension plan; any impairment of our intangible assets; our ability to secure, protect and maintain our intellectual property rights, and our ability to license rights from major gaming console makers and video game publishers to support our gaming business; continued disruptions in the global supply chain; risks associated with changes in the cost or availability of raw materials, transportation, labor, and other necessary supplies and services and the cost of finished goods; the continued global shortage of microchips which are needed in our gaming and computer accessories businesses; risks associated with outsourcing production of certain of our products, information technology systems and other administrative functions; the failure, inadequacy or interruption of our information technology systems or its supporting infrastructure; risks associated with a cybersecurity incident or information security breach, including that related to a disclosure of personally identifiable information; our ability to grow profitably through acquisitions; our ability to successfully integrate acquisitions and achieve the financial and other results anticipated at the time of acquisition, including planned synergies; risks associated with our indebtedness, including limitations imposed by restrictive covenants, our debt service obligations, and our ability to comply with financial ratios and tests; a change in or discontinuance of our stock repurchase program or the payment of dividends; product liability claims, recalls or regulatory actions; the impact of litigation or other legal proceedings; our failure to comply with applicable laws, rules and regulations and self-regulatory requirements, the costs of compliance and the impact of changes in such laws; our ability to attract and retain qualified personnel; the volatility of our stock price; risks associated with circumstances outside our control, including those caused by public health crises, such as the occurrence of contagious diseases like COVID-19, severe weather events, war, terrorism and other geopolitical incidents; and other risks and uncertainties described in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, and in other reports we file with the Securities and Exchange Commission (“SEC”).

ACCO Brands Corporation and
Subsidiaries

Condensed Consolidated Balance
Sheets

 

 

 

 

 

 

 

 

 

June 30,

2022

 

 

December 31,

2021

 

(in millions)

 

(unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

$

 

91.7

 

$

 

41.2

 

Accounts receivable, net

 

 

423.9

 

 

 

416.1

 

Inventories

 

 

471.5

 

 

 

428.0

 

Other current assets

 

 

56.2

 

 

 

39.6

 

Total current assets

 

 

1,043.3

 

 

 

924.9

 

Total property, plant and equipment

 

 

594.7

 

 

 

656.4

 

Less: accumulated depreciation

 

 

(398.7

)

 

 

(441.8

)

Property, plant and equipment, net

 

 

196.0

 

 

 

214.6

 

Right of use asset, leases

 

 

96.8

 

 

 

105.2

 

Deferred income taxes

 

 

105.0

 

 

 

115.9

 

Goodwill

 

 

779.2

 

 

 

802.5

 

Identifiable intangibles, net

 

 

864.6

 

 

 

902.2

 

Other non-current assets

 

 

6.0

 

 

 

26.0

 

Total assets

$

 

3,090.9

 

$

 

3,091.3

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Notes payable

$

 

20.2

 

$

 

9.4

 

Current portion of long-term debt

 

 

33.9

 

 

 

33.6

 

Accounts payable

 

 

254.4

 

 

 

308.2

 

Accrued compensation

 

 

36.1

 

 

 

56.9

 

Accrued customer program liabilities

 

 

98.0

 

 

 

101.4

 

Lease liabilities

 

 

22.4

 

 

 

24.4

 

Current portion of contingent consideration

 

 

2.7

 

 

 

24.8

 

Other current liabilities

 

 

122.8

 

 

 

149.9

 

Total current liabilities

 

 

590.5

 

 

 

708.6

 

Long-term debt, net

 

 

1,124.5

 

 

 

954.1

 

Long-term lease liabilities

 

 

81.9

 

 

 

89.0

 

Deferred income taxes

 

 

147.7

 

 

 

145.2

 

Pension and post-retirement benefit obligations

 

 

194.2

 

 

 

222.3

 

Contingent consideration

 

 

0.3

 

 

 

12.0

 

Other non-current liabilities

 

 

78.9

 

 

 

95.3

 

Total liabilities

 

 

2,218.0

 

 

 

2,226.5

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock

 

 

1.0

 

 

 

1.0

 

Treasury stock

 

 

(43.4

)

 

 

(40.9

)

Paid-in capital

 

 

1,894.7

 

 

 

1,902.2

 

Accumulated other comprehensive loss

 

 

(539.3

)

 

 

(535.5

)

Accumulated deficit

 

 

(440.1

)

 

 

(462.0

)

Total stockholders’ equity

 

 

872.9

 

 

 

864.8

 

Total liabilities and stockholders’ equity

$

 

3,090.9

 

$

 

3,091.3

 

 

ACCO Brands Corporation and
Subsidiaries

Consolidated Statements of Income
(Unaudited)

(In millions, except per share
data)

 

 

 

Three Months Ended
June 30,

 

 

 

Six Months Ended
June 30,

 

 

 

 

2022

 

2021

 

% Change

 

2022

 

2021

 

% Change

Net sales

$

521.0

 

$

517.8

 

 

0.6%

$

962.6

 

$

928.3

 

 

3.7%

Cost of products sold

 

371.0

 

 

353.7

 

 

4.9%

 

693.0

 

 

648.7

 

 

6.8%

Gross profit

 

150.0

 

 

164.1

 

 

(8.6)%

 

269.6

 

 

279.6

 

 

(3.6)%

Operating costs and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

91.6

 

 

97.7

 

 

(6.2)%

 

190.4

 

 

191.7

 

 

(0.7)%

Amortization of intangibles

 

10.5

 

 

11.6

 

 

(9.5)%

 

21.6

 

 

23.6

 

 

(8.5)%

Restructuring charges

 

1.9

 

 

 

 

NM

 

2.2

 

 

3.9

 

 

(43.6)%

Change in fair value of contingent consideration

 

(9.4

)

 

4.9

 

 

NM

 

(6.8

)

 

11.6

 

 

NM

Total operating costs and expenses

 

94.6

 

 

114.2

 

 

(17.2)%

 

207.4

 

 

230.8

 

 

(10.1)%

Operating income

 

55.4

 

 

49.9

 

 

11.0%

 

62.2

 

 

48.8

 

 

27.5%

Non-operating expense (income):

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

10.8

 

 

11.6

 

 

(6.9)%

 

20.5

 

 

24.8

 

 

(17.3)%

Interest income

 

(2.2

)

 

(0.5

)

 

NM

 

(3.6

)

 

(0.6

)

 

NM

Non-operating pension income

 

(1.3

)

 

(2.5

)

 

(48.0)%

 

(2.7

)

 

(3.3

)

 

(18.2)%

Other (income) expense, net

 

(3.7

)

 

(9.0

)

 

(58.9)%

 

(2.8

)

 

3.9

 

 

NM

Income before income tax

 

51.8

 

 

50.3

 

 

3.0%

 

50.8

 

 

24.0

 

 

111.7%

Income tax expense (benefit)

 

12.4

 

 

1.7

 

 

NM

 

14.1

 

 

(4.2

)

 

NM

Net income

$

39.4

 

$

48.6

 

 

(18.9)%

$

36.7

 

$

28.2

 

 

30.1%

 

 

 

 

 

 

 

 

 

 

 

 

 

Per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic income per share

$

0.41

 

$

0.51

 

 

(19.6)%

$

0.38

 

$

0.30

 

 

26.7%

Diluted income per share

$

0.40

 

$

0.50

 

 

(20.0)%

$

0.37

 

$

0.29

 

 

27.6%

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

96.2

 

 

95.5

 

 

 

 

96.2

 

 

95.3

 

 

 

Diluted

 

97.4

 

 

97.2

 

 

 

 

98.0

 

 

96.9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash dividends declared per common share

$

0.075

 

$

0.065

 

 

 

$

0.150

 

$

0.130

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Statistics (as a % of Net sales, except Income tax rate)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
June 30,

 

 

 

Six Months Ended
June 30,

 

 

 

 

2022

 

2021

 

 

 

2022

 

2021

 

 

Gross profit (Net sales, less Cost of products sold)

 

28.8

%

 

31.7

%

 

 

 

28.0

%

 

30.1

%

 

 

Selling, general and administrative expenses

 

17.6

%

 

18.9

%

 

 

 

19.8

%

 

20.7

%

 

 

Operating income

 

10.6

%

 

9.6

%

 

 

 

6.5

%

 

5.3

%

 

 

Income before income tax

 

9.9

%

 

9.7

%

 

 

 

5.3

%

 

2.6

%

 

 

Net income

 

7.6

%

 

9.4

%

 

 

 

3.8

%

 

3.0

%

 

 

Income tax rate

 

23.9

%

 

3.4

%

 

 

 

27.8

%

 

(17.5

)%

 

 

 

 

ACCO Brands Corporation and
Subsidiaries

Condensed Consolidated Statements
of Cash Flows (Unaudited)

 

 

 

 

 

 

Six Months Ended June 30,

 

(in millions)

 

2022

 

 

2021

 

Operating activities

 

 

 

 

 

 

Net income

$

 

36.7

 

$

 

28.2

 

Amortization of inventory step-up

 

 

 

 

 

2.4

 

Payments of contingent consideration

 

 

(9.2

)

 

 

 

Loss on disposal of assets

 

 

(0.2

)

 

 

 

Change in fair value of contingent liability

 

 

(6.8

)

 

 

11.6

 

Depreciation

 

 

19.6

 

 

 

19.6

 

Amortization of debt issuance costs

 

 

1.4

 

 

 

1.5

 

Amortization of intangibles

 

 

21.6

 

 

 

23.6

 

Stock-based compensation

 

 

7.2

 

 

 

9.0

 

Loss on debt extinguishment

 

 

 

 

 

3.7

 

Changes in balance sheet items:

 

 

 

 

 

 

Accounts receivable

 

 

(12.4

)

 

 

(54.5

)

Inventories

 

 

(51.4

)

 

 

(77.9

)

Other assets

 

 

(18.7

)

 

 

(32.2

)

Accounts payable

 

 

(47.2

)

 

 

42.3

 

Accrued expenses and other liabilities

 

 

(34.8

)

 

 

(12.3

)

Accrued income taxes

 

 

(3.7

)

 

 

(20.1

)

Net cash used by operating activities

 

 

(97.9

)

 

 

(55.1

)

Investing activities

 

 

 

 

 

 

Additions to property, plant and equipment

 

 

(7.0

)

 

 

(9.3

)

Proceeds from the disposition of assets

 

 

0.2

 

 

 

 

Cost of acquisitions, net of cash acquired

 

 

 

 

 

15.4

 

Net cash (used) provided by investing activities

 

 

(6.8

)

 

 

6.1

 

Financing activities

 

 

 

 

 

 

Proceeds from long-term borrowings

 

 

218.0

 

 

 

648.8

 

Repayments of long-term debt

 

 

(25.6

)

 

 

(529.2

)

Proceeds of notes payable, net

 

 

11.3

 

 

 

2.2

 

Payment for debt premium

 

 

 

 

 

(9.8

)

Payments for debt issuance costs

 

 

 

 

 

(10.5

)

Dividends paid

 

 

(14.4

)

 

 

(12.4

)

Payments of contingent consideration

 

 

(17.8

)

 

 

 

Repurchases of common stock

 

 

(19.4

)

 

 

 

Payments related to tax withholding for stock-based compensation

 

 

(2.5

)

 

 

(0.9

)

Proceeds from the exercise of stock options

 

 

4.3

 

 

 

2.0

 

Net cash provided by financing activities

 

 

153.9

 

 

 

90.2

 

Effect of foreign exchange rate changes on cash and cash equivalents

 

 

1.3

 

 

 

0.1

 

Net increase in cash and cash equivalents

 

 

50.5

 

 

 

41.3

 

Cash and cash equivalents

 

 

 

 

 

 

Beginning of the period

 

 

41.2

 

 

 

36.6

 

End of the period

$

91.7

 

$

 

77.9

About Non-GAAP Financial Measures

This earnings release contains non-GAAP financial measures. We explain below how we calculate and use each of these non-GAAP financial measures and a reconciliation of our current period and historical non-GAAP financial measures to the most directly comparable GAAP financial measures follows.

We use our non-GAAP financial measures both to explain our results to stockholders and the investment community and in the internal evaluation and management of our business. We believe our non-GAAP financial measures provide management and investors with a more complete understanding of our underlying operational results and trends, facilitate meaningful period-to-period comparisons and enhance an overall understanding of our past and future financial performance.

Our non-GAAP financial measures exclude certain items that may have a material impact upon our reported financial results such as restructuring charges, transaction and integration expenses associated with material acquisitions, the impact of foreign currency fluctuation and acquisitions, unusual tax items and other non-recurring items that we consider to be outside of our core operations. These measures should not be considered in isolation or as a substitute for, or superior to, the directly comparable GAAP financial measures and should be read in connection with the Company’s financial statements presented in accordance with GAAP.

Our non-GAAP financial measures include the following:

Comparable Net Sales : Represents net sales excluding the impact of material acquisitions with current-period foreign operation sales translated at prior-year currency rates. We believe comparable net sales are useful to investors and management because they reflect underlying sales and sales trends without the effect of acquisitions and fluctuations in foreign exchange rates and facilitate meaningful period-to-period comparisons. We sometimes refer to comparable net sales as comparable sales.

Adjusted Gross Profit : Represents gross profit excluding the effect of the amortization of the step-up in inventory from material acquisitions. We believe adjusted gross profit is useful to investors and management because it reflects underlying gross profit without the effect of inventory adjustments resulting from acquisitions that we consider to be outside our core operations and facilitates meaningful period-to-period comparisons.

Adjusted Selling, General and Administrative (SG&A) Expenses : Represents selling, general and administrative expenses excluding transaction and integration expenses related to our material acquisitions. We believe adjusted SG&A expenses are useful to investors and management because they reflect underlying SG&A expenses without the effect of expenses related to acquiring and integrating acquisitions that we consider to be outside our core operations and facilitate meaningful period-to-period comparisons.

Adjusted Operating Income/Adjusted Income Before Taxes/Adjusted
Net Income/Adjusted Net Income Per Diluted Share
 : Represents operating income, income before taxes, net income, and net income per diluted share excluding restructuring charges, the amortization of intangibles, the amortization of the step-up in value of inventory, the change in fair value of contingent consideration, transaction and integration expenses associated with material acquisitions, non-recurring items in interest expense or other income/expense such as expenses associated with debt refinancing, a bond redemption, or a pension curtailment, and other non-recurring items as well as all unusual and discrete income tax adjustments, including income tax related to the foregoing. We believe these adjusted non-GAAP financial measures are useful to investors and management because they reflect our underlying operating performance before items that we consider to be outside our core operations and facilitate meaningful period-to-period comparisons. Senior management’s incentive compensation is derived, in part, using adjusted operating income and adjusted net income per diluted share, which is derived from adjusted net income. We sometimes refer to adjusted net income per diluted share as adjusted earnings per share.

Comparable Adjusted Net Income Per Diluted Share: Represents adjusted net income per diluted share excluding the incremental current year impact of foreign exchange. We sometimes refer to comparable adjusted net income per diluted share as comparable adjusted earnings per share.

Adjusted Income Tax Expense/Rate : Represents income tax expense/rate excluding the tax effect of the items that have been excluded from adjusted income before taxes, unusual income tax items such as the impact of tax audits and changes in laws, significant reserves for cash repatriation, excess tax benefits/losses, and other discrete tax items. We believe our adjusted income tax expense/rate is useful to investors because it reflects our baseline income tax expense/rate before benefits/losses and other discrete items that we consider to be outside our core operations and facilitates meaningful period-to-period comparisons.

Adjusted EBITDA: Represents net income excluding the effects of depreciation, stock-based compensation expense, amortization of intangibles, the change in fair value of contingent consideration, interest expense, net, other (income) expense, net, and income tax expense, the amortization of the step-up in value of inventory, transaction and integration expenses associated with material acquisitions, restructuring charges, non-recurring items in interest expense or other income/expense such as expenses associated with debt refinancing, a bond redemption, or a pension curtailment and other non-recurring items. We believe adjusted EBITDA is useful to investors because it reflects our underlying cash profitability and adjusts for certain non-cash charges, and items that we consider to be outside our core operations and facilitates meaningful period-to-period comparisons.

Free Cash Flow: Represents cash flow from operating activities, excluding cash payments made for contingent earnouts, less cash used for additions to property, plant and equipment, plus cash proceeds from the disposition of assets. We believe free cash flow is useful to investors because it measures our available cash flow for paying dividends, funding strategic material acquisitions, reducing debt, and repurchasing shares.

Net Leverage Ratio: Represents balance sheet debt, plus debt origination costs and less any cash and cash equivalents divided by adjusted EBITDA. We believe that net leverage ratio is useful to investors since the company has the ability to, and may decide to use a portion of its cash and cash equivalents to retire debt.

This earnings release also provides forward-looking non-GAAP comparable net sales, adjusted earnings per share, comparable adjusted earnings per share, free cash flow, adjusted EBITDA, net leverage ratio and adjusted tax rate. We do not provide a reconciliation of forward-looking comparable net sales, adjusted earnings per share, comparable adjusted earnings per share, free cash flow, adjusted EBITDA, net leverage ratio or adjusted tax rate to GAAP because the GAAP financial measure is not accessible on a forward-looking basis and reconciling information is not available without unreasonable effort due to the inherent difficulty of forecasting and quantifying certain amounts that are necessary for such a reconciliation, including adjustments that could be made for restructuring, integration and acquisition-related expenses, the variability of our tax rate and the impact of foreign currency fluctuation and material acquisitions, and other charges reflected in our historical numbers. The probable significance of each of these items is high and, based on historical experience, could be material.

ACCO Brands Corporation and
Subsidiaries

Reconciliation of GAAP to Adjusted
Non-GAAP Information (Unaudited)

(In millions, except per share
data)

 

 

 

The following tables set forth a reconciliation of certain Consolidated Statements of Income information reported in accordance with GAAP to adjusted Non-GAAP Information for the three months ended June 30, 2022 and 2021.

 

 

 

 

 

Three Months Ended June 30, 2022

 

 

 

 

 

SG&A

 

 

%
of Sales

 

 

 

Operating

Income

 

 

%
of Sales

 

 

 

Income before Tax

 

 

%
of Sales

 

 

 

Income Tax

Expense (E)

 

 

Tax
Rate

 

 

 

Net Income

 

 

%
of Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported GAAP

 

$

 

91.6

 

 

 

17.6

%

 

$

 

55.4

 

 

 

10.6

%

 

$

 

51.8

 

 

 

9.9

%

 

$

 

12.4

 

 

 

23.9

%

 

$

 

39.4

 

 

 

7.6

%

 

Reported GAAP diluted income per share (EPS)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

0.40

 

 

 

 

 

Release of charge for Russia business

(A)

 

 

0.3

 

 

 

 

 

 

 

(0.3

)

 

 

 

 

 

 

(0.3

)

 

 

 

 

 

 

(0.1

)

 

 

 

 

 

 

(0.2

)

 

 

 

 

Restructuring charges

 

 

 

 

 

 

 

 

 

 

1.9

 

 

 

 

 

 

 

1.9

 

 

 

 

 

 

 

0.4

 

 

 

 

 

 

 

1.5

 

 

 

 

 

Amortization of intangibles

 

 

 

 

 

 

 

 

 

 

10.5

 

 

 

 

 

 

 

10.5

 

 

 

 

 

 

 

2.7

 

 

 

 

 

 

 

7.8

 

 

 

 

 

Change in fair value of contingent consideration

(B)

 

 

 

 

 

 

 

 

 

(9.4

)

 

 

 

 

 

 

(9.4

)

 

 

 

 

 

 

(2.4

)

 

 

 

 

 

 

(7.0

)

 

 

 

 

Brazil tax credits

(I)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3.8

)

 

 

 

 

 

 

(1.3

)

 

 

 

 

 

 

(2.5

)

 

 

 

 

Other discrete tax items

(J)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.0

 

 

 

 

 

 

 

(3.0

)

 

 

 

 

Adjusted Non-GAAP

 

$

 

91.9

 

 

 

17.6

%

 

$

 

58.1

 

 

 

11.2

%

 

$

 

50.7

 

 

 

9.7

%

 

$

 

14.7

 

 

 

29.0

%

 

$

 

36.0

 

 

 

6.9

%

 

Adjusted diluted income per share (Adjusted EPS)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

0.37

 

 

 

 

 

 

 

Three Months Ended June 30, 2021

 

 

 

 

 

SG&A

 

 

%
of Sales

 

 

 

Operating Income

 

 

%
of Sales

 

 

 

Income before Tax

 

 

%
of Sales

 

 

 

Income Tax Expense (E)

 

 

Tax
Rate

 

 

 

Net Income

 

 

%
of Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported GAAP

 

$

 

97.7

 

 

 

18.9

%

 

$

 

49.9

 

 

 

9.6

%

 

$

 

50.3

 

 

 

9.7

%

 

$

 

1.7

 

 

 

3.4

%

 

$

 

48.6

 

 

 

9.4

%

Reported GAAP diluted income per share (EPS)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

0.50

 

 

 

 

Transaction and integration expenses

(D)

 

 

(0.8

)

 

 

 

 

 

 

0.8

 

 

 

 

 

 

 

0.8

 

 

 

 

 

 

 

0.2

 

 

 

 

 

 

 

0.6

 

 

 

 

Amortization of intangibles

 

 

 

 

 

 

 

 

 

 

11.6

 

 

 

 

 

 

 

11.6

 

 

 

 

 

 

 

3.2

 

 

 

 

 

 

 

8.4

 

 

 

 

Change in fair value of contingent consideration

(B)

 

 

 

 

 

 

 

 

 

4.9

 

 

 

 

 

 

 

4.9

 

 

 

 

 

 

 

1.5

 

 

 

 

 

 

 

3.4

 

 

 

 

Brazil tax credits

(I)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9.1

)

 

 

 

 

 

 

(3.1

)

 

 

 

 

 

 

(6.0

)

 

 

 

Other discrete tax items

(J)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

13.0

 

 

 

 

 

 

 

(13.0

)

 

 

 

Adjusted Non-GAAP

 

$

 

96.9

 

 

 

18.7

%

 

$

 

67.2

 

 

 

13.0

%

 

$

 

58.5

 

 

 

11.3

%

 

$

 

16.5

 

 

 

28.2

%

 

$

 

42.0

 

 

 

8.1

%

Adjusted diluted income per share (Adjusted EPS)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

0.43

 

 

 

 

See “Notes to Reconciliations of GAAP to Adjusted Non-GAAP Information and Net Income to Adjusted EBITDA (Unaudited)” for further information regarding adjusted items.

 

ACCO Brands Corporation and
Subsidiaries

Reconciliation of GAAP to Adjusted
Non-GAAP Information (Unaudited)

(In millions, except per share
data)

 

The following tables set forth a reconciliation of certain Consolidated Statements of Income information reported in accordance with GAAP to adjusted Non-GAAP Information for the six months ended June 30, 2022 and 2021

 

 

 

Six Months Ended June 30, 2022

 

 

 

 

SG&A

 

 

%
of Sales

 

 

 

Operating

Income

 

 

%
of Sales

 

 

 

Income before Tax

 

 

%
of Sales

 

 

 

Income Tax Expense (E)

 

 

Tax
Rate

 

 

 

Net Income

 

 

%
of Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported GAAP

 

$

 

190.4

 

 

 

19.8

%

 

$

 

62.2

 

 

 

6.5

%

 

$

 

50.8

 

 

 

5.3

%

 

$

 

14.1

 

 

 

27.8

%

 

$

 

36.7

 

 

 

3.8

%

Reported GAAP diluted income per share (EPS)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

0.37

 

 

 

 

Charge for Russia business

(A)

 

 

(1.5

)

 

 

 

 

 

 

1.5

 

 

 

 

 

 

 

1.5

 

 

 

 

 

 

 

0.3

 

 

 

 

 

 

 

1.2

 

 

 

 

Restructuring charges

 

 

 

 

 

 

 

 

 

 

2.2

 

 

 

 

 

 

 

2.2

 

 

 

 

 

 

 

0.5

 

 

 

 

 

 

 

1.7

 

 

 

 

Amortization of intangibles

 

 

 

 

 

 

 

 

 

 

21.6

 

 

 

 

 

 

 

21.6

 

 

 

 

 

 

 

5.7

 

 

 

 

 

 

 

15.9

 

 

 

 

Change in fair value of contingent consideration

(B)

 

 

 

 

 

 

 

 

 

(6.8

)

 

 

 

 

 

 

(6.8

)

 

 

 

 

 

 

(1.7

)

 

 

 

 

 

 

(5.1

)

 

 

 

Operating tax gains

(H)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(0.1

)

 

 

 

 

 

 

 

 

 

 

 

 

 

(0.1

)

 

 

 

Brazil tax credits

(I)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3.8

)

 

 

 

 

 

 

(1.3

)

 

 

 

 

 

 

(2.5

)

 

 

 

Other discrete tax items

(J)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1.4

 

 

 

 

 

 

 

(1.4

)

 

 

 

Adjusted Non-GAAP

 

$

 

188.9

 

 

 

19.6

%

 

$

 

80.7

 

 

 

8.4

%

 

$

 

65.4

 

 

 

6.8

%

 

$

 

19.0

 

 

 

29.0

%

 

$

 

46.4

 

 

 

4.8

%

Adjusted diluted income per share (Adjusted EPS)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

0.47

 

 

 

 

Six Months Ended June 30, 2021

Gross Profit

 

 

%
of

Sales

 

 

SG&A

 

 

%
of

Sales

 

 

 

Operating Income

 

 

%
of

Sales

 

 

 

Income before Tax

 

 

%
of

Sales

 

 

 

Income Tax (Benefit) Expense (E)

 

 

Tax

Rate

 

 

 

Net Income

 

%
of Sales

 

Reported GAAP

 

$

 

279.6

 

 

 

30.1

%

 

$

 

191.7

 

 

 

20.7

%

 

$

 

48.8

 

 

 

5.3

%

 

$

 

24.0

 

 

 

2.6

%

 

$

 

(4.2

)

 

 

(17.5

)%

 

$

 

28.2

 

 

 

3.0

%

Reported GAAP diluted income per share (EPS)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

0.29

 

 

 

 

Inventory step-up amortization

(C)

 

 

2.4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2.4

 

 

 

 

 

 

 

2.4

 

 

 

 

 

 

 

0.6

 

 

 

 

 

 

 

1.8

 

 

 

 

Transaction and integration expenses

(D)

 

 

 

 

 

 

 

 

 

(1.5

)

 

 

 

 

 

 

1.5

 

 

 

 

 

 

 

1.5

 

 

 

 

 

 

 

0.4

 

 

 

 

 

 

 

1.1

 

 

 

 

Restructuring charges

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.9

 

 

 

 

 

 

 

3.9

 

 

 

 

 

 

 

1.0

 

 

 

 

 

 

 

2.9

 

 

 

 

Amortization of intangibles

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

23.6

 

 

 

 

 

 

 

23.6

 

 

 

 

 

 

 

6.4

 

 

 

 

 

 

 

17.2

 

 

 

 

Change in fair value of contingent consideration

(B)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

11.6

 

 

 

 

 

 

 

11.6

 

 

 

 

 

 

 

3.2

 

 

 

 

 

 

 

8.4

 

 

 

 

Refinancing costs

(E)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.7

 

 

 

 

 

 

 

1.0

 

 

 

 

 

 

 

2.7

 

 

 

 

Operating tax gain

(H)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(0.2

)

 

 

 

 

 

 

 

 

 

 

 

 

 

(0.2

)

 

 

 

Brazil tax credits

(I)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9.1

)

 

 

 

 

 

 

(3.1

)

 

 

 

 

 

 

(6.0

)

 

 

 

Bond redemption

(F)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9.8

 

 

 

 

 

 

 

2.6

 

 

 

 

 

 

 

7.2

 

 

 

 

Pension curtailment

(G)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1.4

 

 

 

 

 

 

 

0.4

 

 

 

 

 

 

 

1.0

 

 

 

 

Other discrete tax items

(J)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

12.3

 

 

 

 

 

 

 

(12.3

)

 

 

 

Adjusted Non-GAAP

 

$

 

282.0

 

 

 

30.4

%

 

$

 

190.2

 

 

 

20.5

%

 

$

 

91.8

 

 

 

9.9

%

 

$

 

72.6

 

 

 

7.8

%

 

$

 

20.6

 

 

 

28.4

%

 

$

 

52.0

 

 

 

5.6

%

Adjusted diluted income per share (Adjusted EPS)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

0.54

 

 

 

 

See “Notes to Reconciliations of GAAP to Adjusted Non-GAAP Information and Net Income to Adjusted EBITDA (Unaudited)” for further information regarding adjusted items.

 

ACCO Brands Corporation and
Subsidiaries

Reconciliation of Net Income to
Adjusted EBITDA (Unaudited)

(In millions)

 

The following table sets forth a reconciliation of net income reported in accordance with GAAP to Adjusted EBITDA.

 

 

 

 

Three Months Ended
June 30,

 

 

 

 

 

Six Months Ended
June 30,

 

 

 

 

 

 

 

2022

 

 

2021

 

 

% Change

 

 

2022

 

 

2021

 

 

% Change

 

Net income

 

$

 

39.4

 

$

 

48.6

 

 

 

(18.9

)%

$

 

36.7

 

$

 

28.2

 

 

 

30.1

%

Inventory step-up amortization

(C)

 

 

 

 

 

 

 

NM

 

 

 

 

 

 

2.4

 

 

 

(100.0

)%

Transaction and integration expenses

(D)

 

 

 

 

 

0.8

 

 

 

(100.0

)%

 

 

 

 

 

1.5

 

 

 

(100.0

)%

Stock-based compensation

 

 

 

2.3

 

 

 

4.2

 

 

 

(45.2

)%

 

 

7.2

 

 

 

9.0

 

 

 

(20.0

)%

Depreciation

 

 

 

9.7

 

 

 

10.0

 

 

 

(3.0

)%

 

 

19.6

 

 

 

19.6

 

 

 

%

(Release) charge for Russia business

(A)

 

 

(0.3

)

 

 

 

 

NM

 

 

 

1.5

 

 

 

 

 

NM

 

Amortization of intangibles

 

 

 

10.5

 

 

 

11.6

 

 

 

(9.5

)%

 

 

21.6

 

 

 

23.6

 

 

 

(8.5

)%

Restructuring charges

 

 

 

1.9

 

 

 

 

 

NM

 

 

 

2.2

 

 

 

3.9

 

 

 

(43.6

)%

Change in fair value of contingent consideration

(B)

 

 

(9.4

)

 

 

4.9

 

 

NM

 

 

 

(6.8

)

 

 

11.6

 

 

NM

 

Pension curtailment

(G)

 

 

 

 

 

 

 

NM

 

 

 

 

 

 

1.4

 

 

 

(100.0

)%

Interest expense, net

 

 

 

8.6

 

 

 

11.1

 

 

 

(22.5

)%

 

 

16.9

 

 

 

24.2

 

 

 

(30.2

)%

Other (income) expense, net

 

 

 

(3.7

)

 

 

(9.0

)

 

 

(58.9

)%

 

 

(2.8

)

 

 

3.9

 

 

NM

 

Income tax expense (benefit)

 

 

 

12.4

 

 

 

1.7

 

 

NM

 

 

 

14.1

 

 

 

(4.2

)

 

NM

 

Adjusted EBITDA (non-GAAP)

 

$

 

71.4

 

$

 

83.9

 

 

 

(14.9

)%

$

 

110.2

 

$

 

125.1

 

 

 

(11.9

)%

Adjusted EBITDA as
a % of Net Sales

 

 

 

13.7

%

 

 

16.2

%

 

 

 

 

 

11.4

%

 

 

13.5

%

 

 

 

 

See “Notes to Reconciliations of GAAP to Adjusted Non-GAAP Information and Net Income to Adjusted EBITDA (Unaudited)” for further information regarding adjusted items.

Reconciliation of Net Cash Used by
Operating Activities to Free Cash Flow (Unaudited)

(In millions)

 

The following table sets forth a reconciliation of net cash provided by operating activities reported in accordance with GAAP to Free Cash Flow.

 

 

 

Three Months Ended

June 30, 2022

 

 

Three Months Ended

June 30, 2021

 

 

Six Months Ended

June 30, 2022

 

 

Six Months Ended

June 30, 2021

 

Net cash provided (used) by operating activities

$

 

6.3

 

$

 

(12.7

)

$

 

(97.9

)

$

 

(55.1

)

Net cash (used) provided by:

 

 

 

 

 

 

 

 

 

 

 

 

Additions to property, plant and equipment

 

 

(3.6

)

 

 

(5.5

)

 

 

(7.0

)

 

 

(9.3

)

Proceeds from the disposition of assets

 

 

0.2

 

 

 

 

 

 

0.2

 

 

 

 

Payments of contingent consideration

 

 

9.2

 

 

 

 

 

 

9.2

 

 

 

 

Free cash flow (non-GAAP)

$

 

12.1

 

$

 

(18.2

)

$

 

(95.5

)

$

 

(64.4

)

 

Notes to Reconciliations of GAAP
to Adjusted Non-GAAP Information and Net Income to Adjusted EBITDA
(Unaudited)

 

A.

Represents a net charge to operating expense related to our Russia business.

B.

Represents the change in fair value of the contingent consideration for the PowerA acquisition. The change in fair value of the contingent consideration is assessed every quarter and is included as expense/income in the consolidated statements of income.

C.

Represents the amortization of step-up in the value of inventory associated with the PowerA acquisition.

D.

Represents transaction and integration expenses associated with our acquisitions.

E.

Represents the write-off of debt issuance costs and other costs associated with the Company’s 2021 debt refinancing and discharge of its obligations on the senior unsecured notes due in 2024.

F.

Represents a call premium on the 2021 redemption of the senior unsecured notes due in 2024.

G.

Represents a pension curtailment related to restructuring projects.

H.

Represents gains related to the release of unneeded reserves for certain operating taxes.

I.

Represents certain indirect tax credits related to Brazil.

J.

The adjustments to income tax expense include the effects of the adjustments outlined above and discrete tax adjustments.

ACCO Brands Corporation and
Subsidiaries

Supplemental Business Segment
Information and Reconciliation (Unaudited)

(In millions)

 

 

 

2022

 

2021

 

Changes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reported

 

 

 

 

 

Adjusted

 

 

Operating

 

 

 

 

Reported

 

 

 

 

 

Adjusted

 

 

Operating

 

 

 

 

 

 

Adjusted

 

 

Adjusted

 

 

 

 

 

 

 

 

Operating

 

 

 

 

 

Operating

 

 

Income

 

 

 

 

Operating

 

 

 

 

 

Operating

 

 

Income

 

 

 

 

 

 

Operating

 

 

Operating

 

 

 

 

 

Reported

 

 

Income

 

 

Adjusted

 

 

Income

 

 

(Loss)

 

Reported

 

 

Income

 

 

Adjusted

 

 

Income

 

 

(Loss)

 

Net Sales

 

 

Net Sales

 

Income

 

 

Income

 

Margin

 

 

 

Net Sales

 

 

(Loss)

 

 

Items

 

 

(Loss)

 

 

Margin

 

Net Sales

 

 

(Loss)

 

 

Items

 

 

(Loss)

 

 

Margin

 

$

 

 

%

 

(Loss) $

 

 

(Loss) %

 

Points

 

Q1:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands North America

$

 

208.5

 

$

 

13.9

 

$

 

5.9

 

$

 

19.8

 

 

9.5%

$

 

188.8

 

$

 

(0.7

)

$

 

11.9

 

$

 

11.2

 

 

5.9%

$

 

19.7

 

 

10.4%

$

 

8.6

 

 

76.8%

 

 

360

 

ACCO Brands EMEA

 

 

156.1

 

 

 

5.6

 

 

 

3.5

 

 

 

9.1

 

 

5.8%

 

 

156.9

 

 

 

16.8

 

 

 

4.4

 

 

 

21.2

 

 

13.5%

 

 

(0.8

)

 

(0.5)%

 

 

(12.1

)

 

(57.1)%

 

 

(770

)

ACCO Brands International

 

 

77.0

 

 

 

4.2

 

 

 

2.0

 

 

 

6.2

 

 

8.1%

 

 

64.8

 

 

 

0.6

 

 

 

2.5

 

 

 

3.1

 

 

4.8%

 

 

12.2

 

 

18.8%

 

 

3.1

 

 

100.0%

 

 

330

 

Corporate

 

 

 

 

 

(16.9

)

 

 

4.4

 

 

 

(12.5

)

 

 

 

 

 

 

 

(17.8

)

 

 

6.9

 

 

 

(10.9

)

 

 

 

 

 

 

 

 

 

(1.6

)

 

 

 

 

 

Total

$

 

441.6

 

$

 

6.8

 

$

 

15.8

 

$

 

22.6

 

 

5.1%

$

 

410.5

 

$

 

(1.1

)

$

 

25.7

 

$

 

24.6

 

 

6.0%

$

 

31.1

 

 

7.6%

$

 

(2.0

)

 

(8.1)%

 

 

(90

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Q2:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands North America

$

 

306.6

 

$

 

50.7

 

$

 

6.5

 

$

 

57.2

 

 

18.7 %

$

 

295.1

 

$

 

53.8

 

$

 

6.1

 

$

 

59.9

 

 

20.3%

$

 

11.5

 

 

3.9%

$

 

(2.7

)

 

(4.5)%

 

 

(160

)

ACCO Brands EMEA

 

 

137.9

 

 

 

(1.5

)

 

 

3.6

 

 

 

2.1

 

 

1.5 %

 

 

157.0

 

 

 

9.9

 

 

 

3.9

 

 

 

13.8

 

 

8.8%

 

 

(19.1

)

 

(12.2)%

 

 

(11.7

)

 

(84.8)%

 

 

(730

)

ACCO Brands International

 

 

76.5

 

 

 

6.3

 

 

 

2.3

 

 

 

8.6

 

 

11.2 %

 

 

65.7

 

 

 

2.8

 

 

 

2.0

 

 

 

4.8

 

 

7.3%

 

 

10.8

 

 

16.4%

 

 

3.8

 

 

79.2%

 

 

390

 

Corporate

 

 

 

 

 

(0.1

)

 

 

(9.7

)

 

 

(9.8

)

 

 

 

 

 

 

 

(16.6

)

 

 

5.3

 

 

 

(11.3

)

 

 

 

 

 

 

 

 

 

1.5

 

 

 

 

 

 

Total

$

 

521.0

 

$

 

55.4

 

$

 

2.7

 

$

 

58.1

 

 

11.2 %

$

 

517.8

 

$

 

49.9

 

$

 

17.3

 

$

 

67.2

 

 

13.0%

$

 

3.2

 

 

0.6%

$

 

(9.1

)

 

(13.5)%

 

 

(180

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Q3:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands North America

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

287.5

 

$

 

34.6

 

$

 

7.0

 

$

 

41.6

 

 

14.5%

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands EMEA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

161.1

 

 

 

13.4

 

 

 

3.9

 

 

 

17.3

 

 

10.7%

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands International

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

78.1

 

 

 

7.3

 

 

 

2.5

 

 

 

9.8

 

 

12.5%

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(16.7

)

 

 

5.0

 

 

 

(11.7

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

526.7

 

$

 

38.6

 

$

 

18.4

 

$

 

57.0

 

 

10.8%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Q4:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands North America

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

271.0

 

$

 

34.2

 

$

 

7.7

 

$

 

41.9

 

 

15.5%

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands EMEA

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

187.9

 

 

 

21.6

 

 

 

3.3

 

 

 

24.9

 

 

13.3%

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands International

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

111.4

 

 

 

20.9

 

 

 

2.0

 

 

 

22.9

 

 

20.6%

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13.1

)

 

 

2.5

 

 

 

(10.6

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

 

570.3

 

$

 

63.6

 

$

 

15.5

 

$

 

79.1

 

 

13.9%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

YTD:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands North America

$

 

515.1

 

$

 

64.6

 

$

 

12.4

 

$

 

77.0

 

 

14.9%

$

 

1,042.4

 

$

 

121.9

 

$

 

32.7

 

$

 

154.6

 

 

14.8%

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands EMEA

 

 

294.0

 

 

 

4.1

 

 

 

7.1

 

 

 

11.2

 

 

3.8%

 

 

662.9

 

 

 

61.7

 

 

 

15.5

 

 

 

77.2

 

 

11.6%

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands International

 

 

153.5

 

 

 

10.5

 

 

 

4.3

 

 

 

14.8

 

 

9.6%

 

 

320.0

 

 

 

31.6

 

 

 

9.0

 

 

 

40.6

 

 

12.7%

 

 

 

 

 

 

 

 

 

 

 

 

 

Corporate

 

 

 

 

 

(17.0

)

 

 

(5.3

)

 

 

(22.3

)

 

 

 

 

 

 

 

(64.2

)

 

 

19.7

 

 

 

(44.5

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

$

 

962.6

 

$

 

62.2

 

$

 

18.5

 

$

 

80.7

 

 

8.4%

$

 

2,025.3

 

$

 

151.0

 

$

 

76.9

 

$

 

227.9

 

 

11.3%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See “Notes to Reconciliations of GAAP to Adjusted Non-GAAP Information and Net Income to Adjusted EBITDA (Unaudited)” for further information regarding adjusted items.

 

ACCO Brands Corporation and
Subsidiaries

Supplemental Net Sales Change
Analysis (Unaudited)

 

 

 

% Change – Net Sales

 

$ Change – Net Sales (in millions)

 

 

 

 

GAAP

Non-GAAP

 

 

GAAP

Non-GAAP

 

 

 

 

 

 

 

 

Comparable

 

 

 

 

 

 

Comparable

 

 

 

 

Net Sales

 

Currency

 

Net Sales

 

 

Net Sales

 

Currency

 

Net Sales

 

Comparable

 

 

Change

 

Translation

 

Change

 

 

Change

 

Translation

 

Change

 

Net Sales

Q1 2022:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands North America

 

10.4 %

 

— %

 

10.4 %

 

$

19.7

$

$

19.7

$

208.5

ACCO Brands EMEA

 

(0.5)%

 

(7.9)%

 

7.4 %

 

 

(0.8)

 

(12.4)

 

11.6

 

168.5

ACCO Brands International

 

18.8 %

 

(3.9)%

 

22.7 %

 

 

12.2

 

(2.5)

 

14.7

 

79.5

Total

 

7.6 %

 

(3.6)%

 

11.2 %

 

$

31.1

$

(14.9)

$

46.0

$

456.5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Q2 2022:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands North America

 

3.9 %

 

(0.5)%

 

4.4 %

 

$

11.5

$

(1.4)

$

12.9

$

308.0

ACCO Brands EMEA

 

(12.2)%

 

(12.6)%

 

0.4 %

 

 

(19.1)

 

(19.8)

 

0.7

 

157.7

ACCO Brands International

 

16.4 %

 

(3.7)%

 

20.1 %

 

 

10.8

 

(2.4)

 

13.2

 

78.9

Total

 

0.6 %

 

(4.6)%

 

5.2 %

 

$

3.2

$

(23.6)

$

26.8

$

544.6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2022 YTD:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ACCO Brands North America

 

6.4 %

 

(0.3)%

 

6.7 %

 

$

31.2

$

(1.4)

$

32.6

$

516.5

ACCO Brands EMEA

 

(6.3)%

 

(10.3)%

 

4.0 %

 

 

(19.9)

 

(32.2)

 

12.3

 

326.2

ACCO Brands International

 

17.6 %

 

(3.8)%

 

21.4 %

 

 

23.0

 

(4.9)

 

27.9

 

158.4

Total

 

3.7 %

 

(4.1)%

 

7.8 %

 

$

34.3

$

(38.5)

$

72.8

$

1,001.1

(A) Comparable net sales represents net sales excluding material acquisitions and with current-period foreign operation sales translated at the prior-year currency rates.

 

Christopher McGinnis
Investor Relations
(847) 796-4320

Julie McEwan
Media Relations
(937) 974-8162

Source: ACCO Brands Corporation